Page last updated: 2024-11-04

ketanserin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ketanserin is a selective serotonin antagonist that blocks serotonin receptors (specifically 5-HT2 receptors). It was originally developed as an antihypertensive drug, but its effects on serotonin have led to its investigation in a range of other conditions, including anxiety, depression, and migraine. Ketanserin's synthesis involves a multi-step process starting with a benzophenone derivative. Its importance lies in its ability to modulate serotonin activity, impacting neurotransmission and various physiological processes. The study of ketanserin is driven by its potential therapeutic applications in various disorders related to serotonin dysfunction.'

Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3822
CHEMBL ID51
CHEBI ID6123
SCHEMBL ID34294
MeSH IDM0011983

Synonyms (129)

Synonym
AC-2024
ketaserin
r 41,468
c22h22fn3o3
3-(2-(4-(p-fluorobenzoyl)piperidino)ethyl)-2,4-(1h,3h)-quinazolinedione
2,4(1h,3h)-quinazolinedione, 3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-
ketanserine [inn-french]
ketanserina [inn-spanish]
einecs 277-680-2
ketanserinum [inn-latin]
BRD-K49671696-347-02-8
BRD-K49671696-001-02-1
gtpl88
r41 468
gtpl197
perketal
taseron
r-41468
serefrex
3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1h,3h)-dione
NCGC00024865-01
tocris-0908
PDSP1_000639
BIOMOL-NT_000096
PDSP2_000634
BPBIO1_001356
[3h]-ketanserin
r-41,468
chembl51 ,
3-(2-(4-(4-fluorobenzoyl)piperidinol)ethyl)-2,4(1h,3h)-quinazolinedione
bdbm21395
r41,468
74050-98-9
ketanserin
C07464
ketanserin (usan/inn)
D02363
NCGC00024865-05
NCGC00024865-02
NCGC00024865-03
SPECTRUM2_001713
SPBIO_001726
SPECTRUM1505346
NCGC00024865-04
NCGC00021146-01
r 41468
ketanserinum
ketanserine
CHEBI:6123 ,
3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1h,3h)-dione
3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1h-quinazoline-2,4-dione
ketanserina
HMS2090H18
HMS2094I03
NCGC00021146-07
L000764
nsc-758959
FT-0653664
HMS1923O11
3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-1h-quinazoline-2,4-dione
NCGC00021146-06
3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1h-quinazoline-2,4-dione;ketanserin
A838000
[3h]ketanserin
NCGC00021146-05
NCGC00021146-02
NCGC00021146-03
NCGC00021146-04
NCGC00021146-08
97f9de4ct4 ,
ketanserin [usan:inn:ban]
unii-97f9de4ct4
nsc758959
pharmakon1600-01505346
dtxcid103188
tox21_110865
dtxsid3023188 ,
cas-74050-98-9
CCG-39512
vulketan gel
FT-0630827
AKOS015895130
ketanserin [usan]
ketanserin [mi]
ketanserin [mart.]
ketanserin [who-dd]
ketanserin [inn]
S2232
3-(2-(4-(4-fluorobenzoyl)piperidin-1-yl)-ethyl)quinazoline-2,4(1h,3h)-dione
ketanserin, ketanserin tartrate hydrate, ketanserin tartrate
smr001550601
MLS006010073
SCHEMBL34294
tox21_110865_1
NCGC00021146-09
3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4-(1h,3h)-quinazolinedione
3-{2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl}-2,4(1h,3h)-quinazolinedione
3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]-ethyl]-2,4-[1h, 3h]-quinazolinedione
3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1h,3h)-quinazolinedione
3-(2-(4-(4-fluorobenzoyl)piperidin-1-yl)ethyl)quinazoline-2,4(1h,3h)-dione
F2173-1039
W-104435
3-(2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl)-2,4(1h,3h)-quinazolinedione #
3-[2-[4-(p-fluorobenzoyl)piperidino]ethyl]-2,4-(1h,3h)-quinazolinedione
(+)-3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1h,3h)-quinazolinedione
2,4(1h,3h)-quinazolinedione, 3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-
3-{2-[4-(4-fluoro-benzoyl)-piperidin-1-yl]-ethyl}-1h-quinazoline-2,4-dione
K0051
GS-3601
3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-1,2,3,4-tetrahydroquinazoline-2,4-dione
HMS3655H14
mfcd00083392
CS-6055
HY-10562
SBI-0051158.P003
NCGC00021146-12
SW196882-3
DB12465
2,4(1h,3h)-quinazolinedione,3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-
Q415997
Z2216887910
ketanserin (vulketan gel)
2,4(1h,3h)quinazolinedione,3-(2-(4-(4-fluorobenzoyl)-1-piperidinyl)ethyl)-
kentanserin
SDCCGSBI-0051158.P004
HMS3887G17
NCGC00021146-22
SY053064
3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]quinazoline-2,4(1h,3h)-dione

Research Excerpts

Overview

Ketanserin is an anti-hypertensive drug that is increasingly being used parenterally in the treatment of pre-eclampsia. It is a selective 5-hydroxytryptamine (serotonin)-2A receptor (5-HT2AR) antagonist.

ExcerptReferenceRelevance
"Ketanserin is a selective 5-hydroxytryptamine (serotonin)-2A receptor (5-HT2AR) antagonist. "( Effects of ketanserin on experimental colitis in mice and macrophage function.
Feng, Y; Jiang, W; Liu, F; Shao, L; Shen, J; Xiao, J; Zheng, P, 2016
)
2.27
"Ketanserin is an anti-hypertensive drug with an ability to reduce blood pressure variability (BPV) in acute experiments in spontaneously hypertensive rats (SHRs)."( Effects of long-term treatment with ketanserin on blood pressure variability and end-organ damage in spontaneously hypertensive rats.
Du, WM; Liu, JG; Miao, CY; Shen, FM; Su, DF; Yang, XQ, 2003
)
1.32
"Ketanserin is an antihypertensive drug that is increasingly being used parenterally in the treatment of pre-eclampsia. "( Population pharmacokinetics of ketanserin in pre-eclamptic patients and its association with antihypertensive response.
Hanff, LM; Steegers, EA; Visser, W; Vulto, AG, 2005
)
2.06
"Ketanserin is a selective 5-HT2-receptor antagonist. "( [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
Prostran, M,
)
1.8
"Ketanserin is a recently developed selective 5-HT2 receptor antagonist, reportedly effective against both platelet and vascular 5-HT activation."( Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
Buczko, W; De Gaetano, G; Gambino, MC, 1984
)
1.25
"ketanserin is a potent, competitive antagonist of 5-HT but a weak antagonist of NE and 2."( Tryptaminergic receptors in the bovine pulmonary vasculature: effects of ketanserin.
Eyre, P; Ogunbiyi, PO, 1984
)
1.22
"Ketanserin is a new and interesting alternative in the treatment of hypertension."( Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Svensson, A, 1983
)
2.43
"Ketanserin was found to be a competitive antagonist of the noradrenaline-induced constrictions (pA2 = 7.5)."( Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilation.
McLennan, PL; Taylor, DA, 1984
)
1.35
"Ketanserin is a new, specific serotonin receptor blocking agent, which causes vasodilatation, presumably by an action on the vascular wall. "( Ketanserin in essential hypertension: effects during rest and exercise.
Berglund, G; Hedner, T; Persson, B, 1983
)
3.15
"Ketanserin is a 5HT-2 antagonist with no mixed receptor agonist-antagonist activity."( [Symptomatic relief of carcinoid syndrome by ketanserin. A case].
Cella, G; Luzzatto, G; Pozza, M, 1995
)
1.27
"Ketanserin is a highly selective S2-serotonergic antagonist with additional alpha-adrenergic blocking activity, which has been proposed as a therapy for various cardiovascular diseases including hypertension."( Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
Frishman, WH; Huberfeld, S; Kumar, A; Okin, S; Shareef, B; Wang, YH, 1995
)
1.01
"Ketanserin (1) is a fairly selective 5-HT2 antagonist that binds both at 5-HT2A and 5-HT2C receptors. "( Ketanserin analogues: the effect of structural modification on 5-HT2 serotonin receptor binding.
Arruda, K; Glennon, RA; Ismaiel, AM; Teitler, M, 1995
)
3.18
"2. Ketanserin was found to be a competitive antagonist at 5-HT2 receptors (pA2 = 9.19) and alpha 1-adrenoceptors (pA2 = 7.52)."( Influence of alpha 1-adrenoceptor antagonism of ketanserin on the nature of its 5-HT2 receptor antagonism.
Marwood, JF, 1994
)
1.06
"Ketanserin is a serotonin S2-receptor antagonist that inhibits the platelet activation and vasoconstriction induced by serotonin and also inhibits the mitogenic effect of serotonin on vascular smooth muscle cells."( Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
Ball, SG; Decoster, O; Emanuelsson, H; Heyndrickx, GR; Klein, W; Liberman, H; Rutsch, W; Schroeder, E; Serruys, PW; Tijssen, JP, 1993
)
2.09
"Ketanserin is an antihypertensive drug with affinity to both serotonin S2- and alpha 1-adrenoceptors. "( Effects of ketanserin on heart rate and blood pressure variability: implications for the effect on the baroreflex mechanisms.
de Lange, JJ; Kingma, R; Scheffer, GJ; TenVoorde, BJ; Wesseling, KH, 1995
)
2.12
"Ketanserin is a specific antagonist of 5-HT2 and 5-HT1c receptors. "( Ocular hypotensive effect of topical ketanserin in timolol users.
Carpineto, P; Ciancaglini, M; Costagliola, C; Mastropasqua, L, 1997
)
2.01
"Ketanserin is a selective 5-hydroxytryptamine (5-HT2) antagonist with vasodilator properties in the systemic and pulmonary circulation. "( Effect of ketanserin on central haemodynamics and coronary circulation.
Birnie, D; Hillis, WS; Hood, S; Nasser, A, 1998
)
2.15
"Ketanserin is an attractive alternative in the management of severe early-onset preeclampsia."( Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome.
Bolte, AC; Bruinse, HW; Dekker, GA; Kanhai, HH; van Eyck, J; van Geijn, HP, 1999
)
2.47
"Ketanserin is a selective antagonist of serotonin S(2) receptors; moreover, it produces an alpha(1)-blocking effect."( Color doppler imaging of ocular blood flow after topical ketanserin.
Caramazza, R; Cellini, M, 1999
)
1.27
"Ketanserin appears to be a better option than dihydralazine for treatment of severe preeclampsia since fewer maternal complications and side-effects were observed in patients receiving ketanserin."( Ketanserin for the treatment of preeclampsia.
Bolte, AC; Dekker, GA; Gaffar, SF; van Eyck, J; van Geijn, HP, 2001
)
3.2
"Ketanserin appears to be an attractive medicine in the treatment of severe hypertension in pregnancy, but the optimal dosage could not be established."( The optimal dosage of ketanserin for patients with severe hypertension in pregnancy.
de Jeu, RM; Odendaal, HJ; Steyn, DW; van Geijn, HP; van Schie, DL, 2002
)
2.07
"Ketanserin, which is an antagonist at 5-HT2 receptors, when microinfused into the third cerebral ventricle, did not induce significant cardiovascular effects, except for a slight and transitory hypotensive response after the microinfusion of the highest dose (200 micrograms)."( Inhibition by intraventricular microinfusion of ketanserin of the cardiovascular responses to peripheral administration of methoxamine in rats.
De Francesco, EA; Fersini, G; Mollace, V; Nisticò, G,
)
1.11
"Ketanserin is a serotonin S2-receptor antagonist that has previously been shown to reduce blood pressure in hypertensive patients by reducing systemic vascular resistance."( Serotonin antagonism reduces the adverse symptoms of beta blockade.
Chandler, A; Gould, SE; Korlipara, K; Taylor, NA, 1990
)
1
"Ketanserin is a serotonin S2-receptor antagonist introduced for the treatment of arterial hypertension and vasospastic disorders. "( Clinical pharmacokinetics of ketanserin.
Hedner, T; Heykants, J; Persson, B, 1991
)
2.02
"Ketanserin is a 5-HT2 receptor antagonist without partial agonist properties which also possesses weak alpha 1-adrenoceptor antagonistic activity, which may explain its antihypertensive mechanism of action in patients with essential hypertension. "( Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.
Brogden, RN; Sorkin, EM, 1990
)
3.16
"Ketanserin is a specific antagonist of the 5-HT2 serotoninergic receptors; it is located on the smooth muscle cells of the vessel wall, and its stimulation causes vasoconstriction. "( [Evaluation of acute and chronic effects of ketanserin in the treatment of hypertension and hypothesis on a new mechanism of action].
Sechi, LA,
)
1.84
"Ketanserin is a serotonin antagonist with age-related antihypertensive efficacy. "( Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives.
Karpanou, EA; Kourtis, TK; Paleologos, AA; Pitsavos, CE; Toutouzas, PK; Vyssoulis, GP, 1990
)
1.96
"Ketanserin is a serotonin antagonist with alpha-blocking effect."( [Use of ketanserin in anesthesia. A selective S2 serotonin receptor antagonist].
Knudsen, F; Nielsen, LH; Olesen, AS, 1990
)
1.43
"Ketanserin is a selective serotonin2-receptor blocker and by this mechanism decreases peripheral resistance and blood pressure in hypertensives. "( Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure.
Brune, S; Kreuzer, H; Schmidt, T; Tebbe, U, 1990
)
1.99
"Ketanserin is a serotonin S2-receptor antagonist that is an effective antihypertensive agent with a greater blood pressure reduction in older patients. "( Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?
Gould, SE; Hosie, J; Silas, JH, 1990
)
1.98
"Ketanserin is a serotonin S2-receptor antagonist that lowers blood pressure and inhibits platelet aggregation. "( The effects of ketanserin on ventricular ectopic activity in humans.
Dews, I; Gould, SE; Marks, C; Stephens, J; VandenBurg, M, 1990
)
2.07
"Ketanserin is a serotonin antagonist with high affinity for S2-serotonergic receptors, which mediate the vasoconstrictor effects of serotonin. "( Ketanserin: a possible tool for studying the role of serotonin in hypertension.
Boomsma, F; Man in't Veld, AJ; Schalekamp, MA; Wenting, GJ; Woittiez, AJ, 1985
)
3.15
"Ketanserin is a serotonin (S2) blocker that reduces blood pressure (BP) in patients with essential hypertension preferentially by a reduction of peripheral vascular resistance. "( A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension.
Berglund, G; Hedner, T; Persson, B, 1985
)
1.98
"Ketanserin is a 5-HT2 antagonist with alpha-adrenoreceptor blocking activity. "( Ketanserin in the acute management of severe hypertension.
Kincaid-Smith, P; Murphy, BF; Whitworth, JA, 1985
)
3.15
"Ketanserin is an antihypertensive compound that binds to 5-HT2 receptors as well as to alpha 1-adrenoceptors. "( Effects of ketanserin on hemodynamics and baroreflex effects in conscious spontaneously hypertensive rats.
Smits, JF; Struyker-Boudier, HA; Tijssen, CM; van Essen, H, 1987
)
2.11
"Ketanserin is an arteriolar vasodilator, acting on serotoninergic (5-HT2) and adrenergic (alpha 1) receptors. "( Cardiovascular effects of ketanserin during cold pressure and during isometric and dynamic exercise in hypertensive patients.
Andersson, OK; Hedner, T; Persson, B; Pettersson, A, 1987
)
2.02
"Ketanserin is a novel agent that has been shown to be a specific 5-HT2-serotonergic antagonist. "( Renal hemodynamic effects of ketanserin therapy in essential hypertension.
Gonzalez, DG; Henderson, JD; Kaplan, NM; Lugo, CE; Ralakis, JM; Ram, CV; Zachariah, N, 1987
)
2.01
"- Ketanserin proved to be an effective antihypertensive drug comparable to other blood pressure lowering agents."( [Blood pressure lowering action and tolerance of ketanserin in mono- or combination therapy].
Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Reutter, F; Vallotton, MB, 1989
)
1.09
"Ketanserin is a selective (S2) serotonin receptor antagonist currently under investigation as an antihypertensive. "( Alpha-adrenergic blockade makes minimal contribution to ketanserin's hypotensive effect.
Merrell, WJ; Nadeau, JH; Naslund, TC; Wood, AJ, 1988
)
1.96
"Ketanserin is a selective 5-hydroxytryptamine (5HT2)-receptor antagonist, with modest alpha 1-adrenoceptor activity."( Basic pharmacology of alpha-adrenoceptor antagonists and hybrid drugs.
van Zwieten, PA, 1988
)
1
"Ketanserin is a pure antagonist of serotonin S2-receptors, in blood vessels, platelets and bronchial tissue. "( Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism.
Assogna, G; Ceccanti, M; De Lorenzo, A; Di Giovanni, MG; Lais, A; Pisculli, M; Romeo, M; Valgiusti, FC, 1986
)
3.16
"Ketanserin is a pure and selective antagonist of serotonin S2-receptors in blood vessels, platelets and bronchial tissue. "( Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
Attilia, ML; Berbellini, A; Cavaleri, G; Ceccanti, M; De Lorenzo, A; Di Giovanni, MG; Pisculli, M; Santini, P, 1986
)
3.16
"Ketanserin is a new potent antiserotonergic drug which, unlike previous ones, is selective for S2-serotoninergic receptors and does not have an agonist action. "( Effects of ketanserin on ambulatory blood pressure monitoring in patients with essential hypertension.
Abrignani, MG; Alaimo, G; Cutietta, A; Novo, S; Raineri, A; Strano, A, 1986
)
2.1
"Ketanserin appears to be a new alternative approach in the treatment of mild and moderate essential hypertension."( Ketanserin versus metoprolol in the treatment of essential hypertension.
Bernardiner, E; Lemus, J; Milei, J, 1986
)
2.44
"Ketanserin is a new selective 5-HT2 receptor blocker. "( The influence of ketanserin on hemostasis in vitro.
Arvidsson, S; Bergqvist, D; Haglund, U; Hedner, U; Lindblad, B, 1986
)
2.05
"Ketanserin is a new strong antiserotoninergic drug that, unlike the previous ones, is selective for 5-hydroxytryptamine receptors. "( Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
Abrignani, MG; Adamo, L; Alaimo, G; Avellone, G; Cutietta, A; Giordano, U; Indovina, A; Novo, S; Pinto, A; Strano, A, 1986
)
2.1
"Ketanserin is a new antihypertensive agent with affinity to serotonin (5-HT)2 receptors and at higher concentrations also to alpha 1-adrenoceptors. "( Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat.
Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1985
)
1.98
"Ketanserin is an agent whose main pharmacologic action is antagonism of serotonin (5-hydroxytryptamine, 5HT) receptors of the 5HT2 subtype. "( Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
Hedner, T; Persson, B, 1988
)
1.99
"Ketanserin is a S2-serotonergic receptor antagonist with antihypertensive activity. "( Ketanserin in the treatment of diabetes-associated hypertension.
Beretta-Piccoli, C, 1988
)
3.16
"Ketanserin is a serotonin S2 receptor antagonist with antihypertensive activity. "( Antihypertensive and metabolic effects of ketanserin in diabetic patients with mild hypertension.
Bachmann, C; Beretta-Piccoli, C; Riesen, W; Salvadé, G; Zuppinger, K, 1988
)
1.98
"Ketanserin is an effective antihypertensive drug of moderate potency when given twice daily, with no orthostatic effect."( Ketanserin in essential hypertension: a double-blind, placebo-controlled study.
Cameron, HA; Ramsay, LE, 1985
)
2.43
"Ketanserin is a selective S2-serotoninergic antagonist with additional alpha 1-adrenergic blocking properties."( Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.
Amery, A; Birkenhäger, W; Breckenridge, A; Bühler, F; Distler, A; Dormandy, J; Doyle, A; Frohlich, E; Hansson, L; Vanhoutte, P, 1988
)
1.23
"Ketanserin is a specific S2 serotonergic receptor blocker with possible adrenergic blocking activities that has clinical utility in the treatment of hypertension."( Serotonin antagonism in the treatment of systemic hypertension: the role of ketanserin.
Frishman, WH; Huberfeld, S; Okin, S, 1988
)
1.23
"Ketanserin is a selective serotonin-S2 receptor antagonist with alpha 1-adrenoceptor inhibiting activity. "( Mechanism of action of ketanserin: studies on cardiovascular reactivity in essential and diabetes-associated hypertension.
Beretta-Piccoli, C; Waser, M; Ziegler, WH, 1988
)
2.03
"Ketanserin is a well-known serotonin S2 receptor antagonist but its capacity to inhibit serotonin-induced aggregation ex vivo during chronic administration has been a matter of debate. "( Continuous inhibition of serotonin-induced platelet aggregation during chronic ketanserin administration to man can be detected after plasma pH control.
Arnout, J; Deckmyn, H; van Russelt, M; Vermylen, J, 1987
)
1.94
"Ketanserin proved to be a safe drug to lower blood pressure."( Combined pharmaco-EEG and pharmacopsychological study to estimate CNS effects of ketanserin in hypertensive patients.
Baumgartner, P; Herrmann, WM, 1986
)
1.22

Effects

Ketanserin has a high affinity for the S2-receptors, and thus it will antagonise the stimulating effect of serotonin at these receptors. It has a neutral metabolic-hormonal profile when used as monotherapy for the treatment of hypertension.

Ketanserin has potential utility in the treatment of eclampsia, peripheral vascular disease, carcinoid syndrome, and "shock lung" The drug is not yet a cure-all.

ExcerptReferenceRelevance
"Ketanserin has a similar enhancer effect when morphine, which has a dual role via mu and kappa receptors, was substituted by the antinociceptive spiradoline, a selective κ-opioid agonist."( Ketanserin potentiates morphine-induced antinociception mediated by kappa-receptor activation.
Climent, L; Horga, A; Horga, JF; Peiró, AM; Zapater, P, 2011
)
2.53
"Ketanserin has a moderate effect in cases of acutely developed pulmonary hypertension."( [Use of ketanserin in anesthesia. A selective S2 serotonin receptor antagonist].
Knudsen, F; Nielsen, LH; Olesen, AS, 1990
)
1.43
"Ketanserin has a moderate antihypertensive effect and neutral metabolic-hormonal profile when used as monotherapy for the treatment of hypertension."( Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
Goldstein, DS; Keiser, HR; Levinson, PD; Zimlichman, R, 1988
)
1.28
"Ketanserin has a high affinity for the S2-receptors, and thus it will antagonise the stimulating effect of serotonin at these receptors."( The relevance of serotonin antagonism in the treatment of hypertension.
Doyle, AE, 1988
)
1
"Ketanserin has a moderate antihypertensive effect and neutral metabolic-hormonal profile when used as monotherapy for the treatment of hypertension."( Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin.
Brewer, HB; Goldstein, DS; Keiser, HR; Levinson, PD; Zimlichman, R, 1988
)
1.23
"Ketanserin has a similar enhancer effect when morphine, which has a dual role via mu and kappa receptors, was substituted by the antinociceptive spiradoline, a selective κ-opioid agonist."( Ketanserin potentiates morphine-induced antinociception mediated by kappa-receptor activation.
Climent, L; Horga, A; Horga, JF; Peiró, AM; Zapater, P, 2011
)
2.53
"Ketanserin has higher affinity for 5-HT1D alpha receptors compared to 5-HT1D beta receptors, whereas, GR127935 (N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2(methyl-4(-(5-methyl- 1,2,4-oxadiazol-3-yl)[1,1-biphenyl]-4-carboxamide), a novel and selective 5-HT1D receptor antagonist, has higher affinity for 5-HT1D beta receptors compared to 5-HT1D alpha receptors. "( Differences in the effects of ketanserin and GR127935 on 5-HT-receptor mediated responses in rabbit saphenous vein and guinea-pig jugular vein.
Hill, RG; Longmore, J; Razzaque, Z, 1995
)
2.02
"Ketanserin has potential utility in the treatment of eclampsia, peripheral vascular disease, carcinoid syndrome, and "shock lung." The drug is not yet approved for clinical use in the United States."( Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
Frishman, WH; Huberfeld, S; Kumar, A; Okin, S; Shareef, B; Wang, YH, 1995
)
1.01
"Ketanserin has a moderate effect in cases of acutely developed pulmonary hypertension."( [Use of ketanserin in anesthesia. A selective S2 serotonin receptor antagonist].
Knudsen, F; Nielsen, LH; Olesen, AS, 1990
)
1.43
"Ketanserin has been shown to have both 5-HT2-serotonergic and alpha 1-adrenergic antagonist activity."( Is there alpha-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment?
Ball, SG; Robertson, JI, 1985
)
1.22
"Ketanserin has been shown to antagonise both alpha 1-adrenergic (alpha 1) and 5-HT2-serotonergic (5-HT2) receptors in animal experiments but the findings in humans have been conflicting. "( Ketanserin and alpha 1-adrenergic antagonism in humans.
Ball, SG; Robertson, JI; Zabludowski, JR, 1985
)
3.15
"Ketanserin has alpha 1-antagonist properties, whereas ritanserin is largely devoid of alpha 1-receptor binding affinity."( Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
Ball, SG; Hosie, J; Robertson, JI; Stott, DJ, 1987
)
1.2
"Ketanserin has a moderate antihypertensive effect and neutral metabolic-hormonal profile when used as monotherapy for the treatment of hypertension."( Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
Goldstein, DS; Keiser, HR; Levinson, PD; Zimlichman, R, 1988
)
1.28
"Ketanserin has been suggested as hypotensive drug in man, but it shows as well a specific activity on platelet aggregation."( Ketanserin (S2-receptor blocking agents), hypertension and chronic alcoholism.
Assogna, G; Ceccanti, M; De Lorenzo, A; Di Giovanni, MG; Lais, A; Pisculli, M; Romeo, M; Valgiusti, FC, 1986
)
2.44
"Ketanserin has little or no effect on healthy subjects."( Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
Attilia, ML; Berbellini, A; Cavaleri, G; Ceccanti, M; De Lorenzo, A; Di Giovanni, MG; Pisculli, M; Santini, P, 1986
)
2.44
"Ketanserin has a high affinity for the S2-receptors, and thus it will antagonise the stimulating effect of serotonin at these receptors."( The relevance of serotonin antagonism in the treatment of hypertension.
Doyle, AE, 1988
)
1
"Ketanserin has a moderate antihypertensive effect and neutral metabolic-hormonal profile when used as monotherapy for the treatment of hypertension."( Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin.
Brewer, HB; Goldstein, DS; Keiser, HR; Levinson, PD; Zimlichman, R, 1988
)
1.23
"As ketanserin has alpha 1-adrenoceptor-blocking properties in addition to its serotonin-blocking effects, we sought to define further the mechanism of ketanserin's portal pressure-lowering effect."( Comparison of the hemodynamic responses to ketanserin and prazosin in portal hypertensive rats.
Cummings, SA; Groszmann, RJ; Kaumann, AJ,
)
0.91
"Ketanserin, given orally has been shown to improve blood filterability in patients with myocardial infarction and intermittent claudication."( Serotonin and haemorrheology.
Dormandy, JA, 1987
)
0.99
"Ketanserin has been characterized as a relatively selective antagonist for serotonin (5-HT2) receptors. "( Mechanism of the ocular hypotensive action of ketanserin.
Burke, JA; Chang, FW; Potter, DE, 1985
)
1.97

Actions

Ketanserin failed to produce a greater improvement than placebo in functional and objective clinical signs and symptoms as well as in most subjective assessments. The drug did not inhibit the collagen-induced fall in circulating platelet count, but did significantly increase the rate of return to the basal Platelet count.

ExcerptReferenceRelevance
"Ketanserin caused an increase in AEA concentrations, 180 min after administration."( Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication.
de la Torre, R; Farre, M; Haijen, E; Kuypers, KPC; Olesti, E; Pastor, A; Pizarro, N; Ramaekers, JG, 2018
)
1.2
"Ketanserin was found to inhibit L."( Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani.
Dinesh, N; Kaur, PK; Shamiulla, B; Singh, S, 2014
)
2.57
"Ketanserin does not inhibit vasodilator effects of 5-HT."( Antihypertensive properties of ketanserin (R 41 468).
Janssen, PA; Symoens, J; Van Nueten, JM; Vanhoutte, PM, 1983
)
1.27
"Ketanserin also can inhibit serotonin-induced coronary artery vasoconstriction during percutaneous transluminal coronary angioplasty (PTCA)."( Effect of ketanserin on central haemodynamics and coronary circulation.
Birnie, D; Hillis, WS; Hood, S; Nasser, A, 1998
)
1.42
"Ketanserin inhibited an increase of airway resistance at late phases."( Anti-allergic effects of ketanserin on animal models of allergic reactions.
Goto, S; Kitagaki, K; Koda, A; Miura, T; Nagai, H; Suda, H,
)
1.16
"Ketanserin did not inhibit contractions of any vessels."( Inhibitory effects of nisoldipine on serotonin and potassium induced contractions of porcine coronary and femoral arteries.
Kazda, S, 1991
)
1
"Ketanserin failed to produce a greater improvement than placebo in functional and objective clinical signs and symptoms as well as in most subjective assessments."( Ketanserin in the treatment of systemic sclerosis: a double-blind controlled trial.
Dujardin, P; Fraitag, B; Ortonne, JP; Torzuoli, C, 1989
)
2.44
"Ketanserin did not inhibit the collagen-induced fall in circulating platelet count, but did significantly increase the rate of return to the basal platelet count compared with control."( Involvement of 5-hydroxytryptamine in platelet aggregation in vivo in rats and guinea pigs.
Smith, GM, 1989
)
1
"Ketanserine is able to lower portal pressure of cirrhotic patients at rest as well as during coughing."( [Effect of a serotonin S2 receptor antagonist on portal hypertension due to cirrhosis. Preliminary results of a heart and liver hemodynamic study].
Carlier, J; Deflandre, J; Etienne, M; Pirotte, J,
)
0.85
"Ketanserin did not produce any change in catecholamine concentration.(ABSTRACT TRUNCATED AT 250 WORDS)"( Hemodynamic and neurohumoral effects of ketanserin, a 5-HT2 receptor antagonist in patients with congestive heart failure.
Majid, PA; Morris, WM; Sole, MJ, 1987
)
1.26

Treatment

Ketanserin caused hypotension, enhanced bradycardia, attenuated reflex tachycardia and reversed serotonin (5-HT) responses. All effects were more pronounced in 24-month-old rats than in younger rats. Treatment at doses proposed for clinical use (40-80 mg/day) may carry a risk of ventricular arrhythmias.

ExcerptReferenceRelevance
"Ketanserin treated promastigotes were exogenously supplemented with sterols like ergosterol and cholesterol to rescue cell death."( Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani.
Dinesh, N; Kaur, PK; Shamiulla, B; Singh, S, 2014
)
2.57
"The ketanserin treatment also reduced the repeated inflammation-induced expression of protein kinase gamma (PKCγ) in the membrane of spinal dorsal horn neurons and increased PKCγ protein level in the cytosol."( Blockade of 5-HT2A receptors at the site of inflammation inhibits activation of spinal dorsal horn neurons in rats.
Cai, Q; Hong, Y; Hu, W; Wang, D; Zhang, Y, 2016
)
0.92
"Ketanserin treatment reduced the cortical binding potentials to cerebellar levels, indicating that in vivo (11)C-CIMBI-5 binds selectively to the 5-HT(2A) receptor in the pig brain."( Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET.
Begtrup, M; Ettrup, A; Gillings, N; Hansen, M; Knudsen, GM; Kornum, BR; Madsen, J; Någren, K; Palner, M; Rasmussen, LK; Santini, MA, 2010
)
1.08
"Ketanserin treatment normalized the alterations in the expression of specific genes in the prefrontal cortex of maternally separated animals, including changes in serotonin type 2A receptor messenger RNA expression during postnatal life and in genes associated with G-protein signaling in adulthood."( Postnatal serotonin type 2 receptor blockade prevents the emergence of anxiety behavior, dysregulated stress-induced immediate early gene responses, and specific transcriptional changes that arise following early life stress.
Benekareddy, M; Nair, AR; Vadodaria, KC; Vaidya, VA, 2011
)
1.09
"Ketanserin pretreatment had no effect on the pulmonary vascular reactions, the tracheal pressure difference or the number of circulating platelets or white blood cells."( The role of 5-hydroxytryptamine in the feline response to intravenous infusion of live E. coli.
Arvidsson, S; Falk, A; Haglind, E; Haglund, U, 1983
)
0.99
"The ketanserin-treated groups demonstrated improved cardiac index, decreased pulmonary artery pressures, and smaller arteriovenous oxygen content differences compared to the control group in the early postburn period."( The effect of ketanserin, a specific serotonin antagonist, on burn shock hemodynamic parameters in a porcine burn model.
Holliman, CJ; Larsen, KR; Meuleman, TR; Pace, NL; Port, JD; Stanley, TH; Warden, GD, 1983
)
1.11
"Ketanserin treatment lowered blood pressure consistently, and the ensuing hypotension was more pronounced in 14- and 24-month than in 4-month-old rats."( Aging enhances serotonergic cardiovascular blockade by ketanserin in conscious rats.
Buñag, RD; Davidow, LW; Schmitz, TM, 1994
)
1.26
"In ketanserin-pretreated dogs, methysergide (3-30 micrograms/kg/min) dose-dependently suppressed the 5-HT-induced decrease in RBF."( Serotonin-induced vasoconstriction in dog kidney.
Hisa, H; Satoh, S; Takahashi, T, 1992
)
0.8
"Ketanserin treatment started 30 min after flap surgery also significantly (P less than 0.05) increased the length of skin flap viability (6.1 +/- 0.1 cm) compared with the control."( Augmentation of acute random pattern skin flap viability in the pig.
Forrest, CR; Morris, SF; Pang, CY; Sheffield, WD; Zhong, A, 1992
)
1
"Ketanserin treatment reduced the incidence of nightmares (p less than 0.05 for 20 mg twice daily and 40 mg twice daily) and was an improvement over bendrofluazide treatment in this respect (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)"( Serotonin antagonism reduces the adverse symptoms of beta blockade.
Chandler, A; Gould, SE; Korlipara, K; Taylor, NA, 1990
)
1
"Ketanserin treatment decreased mean left ventricular mass by 9.3% at 3 months (not significant), by 15.3% at 6 months (p less than 0.008), and by 26.2% at 12 months (p less than 0.02), with a tendency towards improvement in left ventricular ejection fraction, which was not statistically significant."( Effects of ketanserin on left ventricular hypertrophy in hypertensive patients.
Alcocer, L; Chávez, A; Cobo, C, 1990
)
1.39
"Ketanserin treatment resulted in: redution in systolic and diastolic blood pressure; significant decrease in heart rate; increase in arteriole and venule internal diameters; increase in blood flow velocities and blood flow volumes; significant decreases in whole blood viscosities at high shear rate (94.5 sec-1) and at low shear rate (0.376 sec-1), with no change in plasma viscosities; significant shortening of plasma passage times; and marked decreases in blood concentrations of total protein, albumin, and globulin."( Effects of ketanserin on microhemodynamics and hemorheology in patients with essential hypertension.
Konishi, M; Sakakura, M; Tsushima, N, 1990
)
1.39
"On ketanserin treatment, the overall quality of life score was significantly improved (p = 0.002; analysis of variance on log transformed data) compared with the placebo phase."( A placebo-controlled crossover study of ketanserin in elderly hypertensive patients.
Gould, SE; John, SM; McCarthy, GL; McCarthy, ST, 1990
)
1.06
"Ketanserin treatment is also associated with prolongation of the corrected QT interval."( The effects of ketanserin on ventricular ectopic activity in humans.
Dews, I; Gould, SE; Marks, C; Stephens, J; VandenBurg, M, 1990
)
1.35
"The ketanserin treated group reported a 16.7% improvement in symptom score (p less than 0.05) relative to the end of the run-in phase compared with a 2.4% (NS) improvement in the placebo group."( Ketanserin and capillary flow in Raynaud's phenomenon.
Black, C; Rawlinson, DW; Tooke, JE; Williams, SA, 1990
)
2.2
"4. Ketanserin treatment was associated with significant changes in supine pulse rate (-8 beats min-1, P less than 0.05) and corrected QT interval (+27 ms, P less than 0.05)."( Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker.
Ramsay, LE; Solomon, SA; Waller, PC, 1987
)
1.15
"Ketanserin treatment tended to normalize these protein levels in such patients."( Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
Attilia, ML; Berbellini, A; Cavaleri, G; Ceccanti, M; De Lorenzo, A; Di Giovanni, MG; Pisculli, M; Santini, P, 1986
)
2.44
"On Ketanserin treatment DBP measurements show a significant increase in the digit to brachial systolic blood pressure index (DBI) after cold provocation."( Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial.
Skotnicki, SH; van de Wal, HJ; van Lier, HJ; Wijn, PF, 1985
)
1.06
"Ketanserin-treated dogs had similar pulmonary hypertension even though more significant decreases in arterial pressure and systemic vascular resistance characterized the systemic effects of ketanserin."( Effects of serotonin inhibition in air embolism in dogs.
Domb, M; Goldstein, J; Lignan, H; Vincent, JL, 1988
)
1
"Ketanserin treatment administered over a period of 8 weeks, decreased arterial pressure in patients with essential hypertension and, to a lesser extent, in diabetics, but not in normal subjects."( Mechanism of action of ketanserin: studies on cardiovascular reactivity in essential and diabetes-associated hypertension.
Beretta-Piccoli, C; Waser, M; Ziegler, WH, 1988
)
1.31
"Ketanserin treatment was discontinued in one patient owing to dizziness and anxiety."( Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác, J; Rovenský, J; Tauchmannová, H; Zitnan, D, 1985
)
1.39
"Treatment with ketanserin attenuated bleomycin-induced PH (increased RVSP and RVH) and pulmonary vascular remodeling (decreased vessel density and increased muscularization of small vessels)."( Serotonin 2A receptor inhibition protects against the development of pulmonary hypertension and pulmonary vascular remodeling in neonatal mice.
Delaney, C; Fisher, S; Maltzahn, J; Nozik-Grayck, E; Sherlock, L; Wright, C, 2018
)
0.82
"Treatment with ketanserine resulted in an antidepressant-like effect in prenatally stressed OVX females in the FST as compared to the control group."( [Pecularities for action of combined administration of NAN-190 and ketanserine with low dose of 17β-estradiol on depression-like behavior in prenatally stressed ovariectomized rats].
Akulova, VK; Fedotova, IuO; Ordian, NÉ; Pivina, SG, 2015
)
0.99
"Treatment with ketanserin attenuated the progression of experimental colitis in the mice, as indicated by body weight assessment, colon length, histological scores and cytokine release."( Effects of ketanserin on experimental colitis in mice and macrophage function.
Feng, Y; Jiang, W; Liu, F; Shao, L; Shen, J; Xiao, J; Zheng, P, 2016
)
1.16
"Pretreatment with ketanserin inhibited neurophysiological modifications, reduced the correlation between alpha and visual effects, and attenuated the intensity of the subjective experience."( Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans.
Alonso, JF; Antonijoan, RM; Barker, S; Feilding, A; Friedlander, P; Mañanas, MÀ; Maqueda, AE; Rabella, M; Riba, J; Rodríguez-Pujadas, A; Romero, S; Valle, M, 2016
)
0.76
"Pretreatment with ketanserin significantly attenuated these effects."( Involvement of pro-nociceptive 5-HT2A receptor in the pathogenesis of medication-overuse headache.
le Grand, SM; Srikiatkhachorn, A; Supornsilpchai, W, 2010
)
0.68
"Treatment with ketanserin during postnatal life blocked the long-lasting effects of maternal separation on anxiety behavior in the open field test and the elevated plus maze. "( Postnatal serotonin type 2 receptor blockade prevents the emergence of anxiety behavior, dysregulated stress-induced immediate early gene responses, and specific transcriptional changes that arise following early life stress.
Benekareddy, M; Nair, AR; Vadodaria, KC; Vaidya, VA, 2011
)
0.72
"Pre-treatment with ketanserin (0.1 mg.kg(-1)), 5HT2 receptor antagonist, shortened the duration of post-serotonin apnea (P < 0.05), but had no effect on the pattern of post-apnoeic breathing."( 5HT2 and 5HT3 receptors' contribution to modeling of post-serotonin respiratory pattern in cats.
Kopczyńska, B; Szereda-Przestaszewska, M, 2004
)
0.64
"Pretreatment with ketanserin did not attenuate the effect of psilocybin on attentional performance, suggesting a primary involvement of the 5-HT1A receptor in the observed deficit."( Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.
Burr, DC; Carter, OL; Hasler, F; Pettigrew, JD; Vollenweider, FX; Wallis, GM, 2005
)
0.65
"Pretreatment with ketanserin blocked the majority of psilocybin's "positive" psychosis-like hallucinogenic symptoms."( Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
Carter, OL; Hasler, F; Liu, GB; Pettigrew, JD; Vollenweider, FX; Wallis, GM, 2007
)
0.66
"Treatment with ketanserin was then continued until 9 months had been completed."( Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Svensson, A, 1983
)
2.05
"Pre-treatment with ketanserin (1.25 mg/kg i.p."( Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist.
De Clerck, F; De Gryse, A; Loots, W; Nevelsteen, A, 1984
)
0.81
"Pretreatment with ketanserin was given to three volunteers and brain activity remained uniformly low."( Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls.
Cantineau, R; Comar, D; Degueldre, C; Guillaume, M; Hermanne, JP; Lemaire, C; Maquet, P; Plenevaux, A; Sadzot, B; Salmon, E, 1995
)
0.61
"Treatment with ketanserin caused hypotension, enhanced bradycardia, attenuated reflex tachycardia, and reversed serotonin (5-HT) responses, with all effects being more pronounced in 24-month-old rats than in younger rats."( Does chronic ketanserin treatment enhance bradycardia in old rats by serotonergic blockade?
Buñag, RD; Davidow, LW, 1998
)
1.01
"Pretreatment with ketanserin (10 microM), a 5-HT2 antagonist, tropisetron (1 microM), a 5-HT3/4 antagonist, SDZ 216-525 (1 to 10 microM) and pindobind (10 microM), both selective 5-HT1A antagonists, or capsaicin (10 microM), which depletes sensory nerves from neuropeptides, had no effect on the inhibition of the cholinergic contraction by 8-OH-DPAT (10 to 30 microM)."( The effects of 8-hydroxy-2-(di-n-propylamino)tetralin on the cholinergic contraction in guinea pig and human airways in vitro.
De Leyn, P; Demedts, MG; Deneffe, G; Dupont, LJ; Pype, JL; Verleden, GM, 1998
)
0.62
"Pretreatment with ketanserin (0.5 mg kg-1, i.v.) or methiothepin (1 mg kg-1, i.v.) did not antagonize the effects of ergotamine."( Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors.
Bom, AH; Heiligers, JP; Saxena, PR; Verdouw, PD, 1989
)
0.6
"Treatment with ketanserin at doses proposed for clinical use (40-80 mg/day) may carry a risk of ventricular arrhythmias."( Prolongation of the QT interval by ketanserin.
Cameron, HA; Ramsay, LE; Waller, PC, 1988
)
0.89
"Pretreatment with ketanserin, a specific 5-HT2 inhibitor, and with methysergide, a mixed 5-HT inhibitor blocked the vasoconstriction induced by 5-HT."( Vasoconstrictor mechanism of 5-hydroxytryptamine in isolated and perfused canine basilar arteries.
Chiba, S; Tsuji, T, 1987
)
0.6
"Treatment with ketanserin was associated with maintenance of PaO2 (KET 207 +/- 5 mm Hg vs C 203 +/- 15 mm Hg), pulmonary shunt (KET 8 +/- 3% vs C 9 +/- 3%), and CI (KET 2.3 +/- 0.1 L/min/m2 vs C 2.8 +/- 0.2 L/min/m2) at control levels and attenuated the Pseudomonas-induced increase in PVRI (873 +/- 37 vs Ps 1599 +/- 89 dyn X sec X cm-5/m2) and SVRI (2089 +/- 287 vs Ps 4542 +/- 774 dyn X sec X cm-5/m2), but did not alter the development of pulmonary edema."( Serotonin receptor blockade improves cardiac output and hypoxia in porcine ARDS.
Kellum, JM; Kuemmerle, JF; Sielaff, TD; Sugerman, HJ; Tatum, JL, 1987
)
0.61

Toxicity

ExcerptReferenceRelevance
" Subsequently, we identified serotonin (5HT), a major platelet product, as having toxic effects on neurons."( Further studies on platelet-mediated neurotoxicity.
Grunfeld, S; Joseph, R; Tsering, C; Welch, KM, 1992
)
0.28
" Thus, sedation as main central nervous system side effect and reduction in salivation as autonomic nervous system side effect of ketanserin could be clearly quantified in comparison to placebo and clonidine."( Central and autonomic nervous system side effects of ketanserin.
Frölich, JC; Ludwig, L; Reimann, IW; Ziegler, G, 1986
)
0.73
" Their use is frequently associated with dose-limiting adverse effects."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
" For detecting side effect liability (ataxia, sedation, impairment of voluntary motor functions), (1) the rota-rod test, (2) measurement of spontaneous motility, (3) the weight-lifting test and (4) the thiopental sleep test were used."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
"Therapeutic indices calculated from the results of these in vivo experiments for the clinically used muscle relaxants are in agreement with their adverse effect profiles in humans."( Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.
Berzsenyi, P; Farkas, S; Kárpáti, E; Kocsis, P; Tarnawa, I,
)
0.13
" However, the neural mechanism by which extracellular 5-HT is elevated to a toxic level for the syndrome remains to be determined."( Assessment of 5-hydroxytryptamine efflux in rat brain during a mild, moderate and severe serotonin-toxicity syndrome.
Huang, X; Krishnamoorthy, S; Ma, Z; Tao, R; Vukovich, NP; Zhang, G, 2009
)
0.35
"Chronic hypertension is associated with adverse perinatal outcomes, although the optimal treatment is unclear."( Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020
)
0.56

Pharmacokinetics

The apparent elimination half-life of ketanserin was 1. The terminal half- life of the parent compound is related to the slow ketanserserin regeneration from the metabolite.

ExcerptReferenceRelevance
" Ketanserin-ol, which by itself does not contribute to the overall pharmacological effect, is partly reoxidised into ketanserin, and it is likely that the terminal half-life of the parent compound is related to the slow ketanserin regeneration from the metabolite."( Clinical pharmacokinetics of ketanserin.
Hedner, T; Heykants, J; Persson, B, 1991
)
1.48
" The elimination half-life of ketanserin was found to be longer in elderly hospital outpatients, but not in our elderly subjects in general practice."( Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?
Gould, SE; Hosie, J; Silas, JH, 1990
)
0.82
" Pharmacokinetic parameters were calculated using noncompartmental analysis based on a statistical moment theory."( Pharmacokinetics of ketanserin in patients with cirrhosis.
Benhamou, JP; Berthelot, P; Fraitag, B; Gaudin, C; Hadengue, A; Lebrec, D; Levron, JC, 1990
)
0.6
" During steady-state therapy the elimination half-life (24."( Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.
Hedner, T; Persson, B; Pettersson, A, 1986
)
0.53
" Individual plasma level-time curves fitted to an open three compartment model and a half-life of 17."( Bioavailability and pharmacokinetics of ketanserin in elderly subjects.
Kurowski, M, 1985
)
0.54
" Pharmacokinetic variables after a single dose were similar to those reported in healthy volunteers, with median values for Cmax 112 ng."( The pharmacokinetics of ketanserin after a single dose and at steady-state in hypertensive subjects.
Ramsay, LE; Tucker, GT; Waller, PC, 1987
)
0.58
" Ketanserin had a terminal half-life of 29."( Pharmacokinetics of ketanserin in patients with essential hypertension.
Hedner, T; Persson, B; Pettersson, A, 1987
)
1.51
" Comparison of plasma Cmax and AUCs indicated that the equilibrium was shifted towards ketanserin-ol."( Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol.
Embrechts, L; Heykants, J; Van Peer, A; Woestenborghs, R, 1986
)
0.75
" ketanserin were characterized by a terminal half-life of 14."( Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.
Gould, S; Heykants, J; Mills, J; Van Peer, A; Woestenborghs, R, 1986
)
1.5
" Plasma concentration declined with a mean terminal half-life of 15."( Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.
Jähnchen, E; Kirch, W; Meinertz, T; Mosler, A; Trenk, D,
)
0.36
" The terminal elimination half-life (term."( Pharmacokinetics of ketanserin in man.
Klotz, U; Okonkwo, PO; Reimann, IW, 1983
)
0.59
" Population pharmacokinetic parameters were assessed using the iterative two-stage Bayesian population procedure."( Population pharmacokinetics of ketanserin in pre-eclamptic patients and its association with antihypertensive response.
Hanff, LM; Steegers, EA; Visser, W; Vulto, AG, 2005
)
0.61
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" A two-compartment linear pharmacokinetic model described the plasma concentration-time profile of ketanserin after single and multiple doses in healthy horses; the terminal half-life was 11."( Pharmacokinetic assessment of ketanserin in the horse.
Aljuffali, IA; Allen, D; Arnold, RD; Brainard, BM; Kwon, S; Moore, JN; Robertson, TP, 2012
)
0.88
"The influence of ageing on the passive and active tension and pharmacodynamic characteristics of intramural coronary arteries from 3-month-old and 2-year-old male Wistar rats was investigated using an isometric myograph."( Effect of ageing on the passive and active tension and pharmacodynamic characteristics of rat coronary arteries: age-dependent increase in sensitivity to 5-HT and K+.
Boonen, HC; Nyborg, NC; Outzen, EM; Sheykhzade, M; Simonsen, AH, 2012
)
0.38
" blood pressure, heart rate, body temperature) can be reduced, possibly due to a pharmacodynamic interaction at the serotonin reuptake transporter (SERT)."( Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug-drug interactions.
Hondebrink, L; Meulenbelt, J; Rietjens, SJ; Westerink, RH, 2012
)
0.38
" Here we tested the pharmacodynamic consequences of these properties in a P-gp deficient mouse model by studying the effects of aripiprazole and of ziprasidone on motor coordination."( Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U, 2013
)
0.39
"Evidence was given that P-gp substrate properties have pharmacodynamic consequences for aripiprazole but not for ziprasidone and thus affect dopamine receptor related motor behaviour."( Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.
Frisch, J; Hiemke, C; Holthoewer, D; Kirschbaum, KM; Schmitt, U, 2013
)
0.39

Compound-Compound Interactions

The long-term safety and efficacy of ketanserin in the treatment of essential hypertension was assessed in monotherapy or in combination with the beta-blocker, metoprolol.

ExcerptReferenceRelevance
"The antihypertensive effect of ketanserin in combination with beta-adrenergic blockade was assessed in a double-blind crossover (4 weeks) manner in 10 patients with essential hypertension."( Antihypertensive properties of ketanserin in combination with beta-adrenergic blocking agents.
Hedner, T; Persson, B, 1985
)
0.84
"In the Swiss Ketanserin Study the antihypertensive efficacy and tolerability of ketanserin (given in 20 or 40 mg doses twice daily) was investigated, after a placebo run-in phase, as monotherapy (n = 68) as well as in combination with either atenolol (100 mg/day) (n = 30) or the potassium-sparing diuretic hydrochlorothiazide (50 mg/day) and amiloride (5 mg/day) (n = 26) in 124 patients with essential hypertension, aged 41 to 82 years."( Antihypertensive efficacy of ketanserin alone or in combination with a beta-blocker or a diuretic: the Swiss Ketanserin Study.
Amstein, R; Beretta-Piccoli, C; Bertel, O; Brunner, HR; Bühler, FR; Follath, F; Solèr, M; Vallotton, M, 1987
)
0.93
" in combination with a beta-adrenergic blocking agent or a diuretic was assessed in an open study in 35 patients with essential hypertension, who had not responded to treatment with beta-blockers, diuretics or their combination."( Ketanserin combined with a beta-blocker or diuretic in essential hypertension. A multicentre study.
Bartoloni, C; Dupont, P; Feltkamp, H; Johnston, CI; Kaindl, F; Steinbach, K; Zilcher, H, 1988
)
1.72
"The long-term safety and efficacy of ketanserin in the treatment of essential hypertension was assessed in monotherapy or in combination with the beta-blocker, metoprolol."( Long-term safety and efficacy of ketanserin in essential hypertension: ketanserin versus or in combination with metoprolol.
Mauersberger, H, 1986
)
0.83
"The antihypertensive properties of ketanserin, a 5-HT2 receptor antagonist, was investigated in combination with beta-adrenoceptor blockade."( Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.
Hedner, T; Persson, B, 1984
)
1.99

Bioavailability

The oral bioavailability of 6-hydroxyketanserin was very low, accounting for its low in vivo activity after oral administration. After a single dose of ketanserins, elderly hypertensives showed about a 60% increase in bioavailability compared with young volunteers. The absolute bioavailability was more than 80% in both rats and dogs.

ExcerptReferenceRelevance
" It is subject to considerable extraction and metabolism in the liver (first-pass effect) and the absolute bioavailability is around 50%."( Clinical pharmacokinetics of ketanserin.
Hedner, T; Heykants, J; Persson, B, 1991
)
0.57
" After a single dose of ketanserin, elderly hypertensives showed about a 60% increase in bioavailability compared with young volunteers."( Could the increased antihypertensive efficacy of ketanserin in the elderly be due to altered pharmacokinetics?
Gould, SE; Hosie, J; Silas, JH, 1990
)
0.84
" Bioavailability ranged between 15 and 60%, indicating a substantial first-pass effect."( Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.
Hedner, T; Persson, B; Pettersson, A, 1986
)
0.53
"The bioavailability of ketanserin has been examined in a cross-over experiment in 21 elderly subjects (aged 59-72 years) by administration of tablets (40 mg), solution (40 mg) and injectable solution (10 mg)."( Bioavailability and pharmacokinetics of ketanserin in elderly subjects.
Kurowski, M, 1985
)
0.85
" The absolute bioavailability of oral ketanserin was more than 80% in both rats and dogs."( Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
Geerts, R; Hendriks, R; Heykants, J; Meuldermans, W; Michiels, M; Monbaliu, J; Woestenborghs, R, 1988
)
0.81
" The oral bioavailability of 6-hydroxyketanserin was very low, accounting for its low in vivo activity after oral administration."( Pharmacokinetic evaluation of the in vitro and in vivo pharmacological profile of the major metabolites of ketanserin in the rat.
Awouters, F; Heykants, J; Leysen, JE; Michiels, M; Schuurkes, J; Van Nueten, JM; Woestenborghs, R, 1988
)
0.76
" Its absolute bioavailability was 48%."( Pharmacokinetics of ketanserin in patients with essential hypertension.
Hedner, T; Persson, B; Pettersson, A, 1987
)
0.6
" administration, peak levels of nearly 200 ng/ml were attained within 10 minutes and the absolute bioavailability was 112 +/- 23%."( Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration.
Gould, S; Heykants, J; Mills, J; Van Peer, A; Woestenborghs, R, 1986
)
0.59
" Orally administered ketanserin was well absorbed and almost completely metabolized in both species."( Excretion and biotransformation of ketanserin after oral and intravenous administration in rats and dogs.
Hendrickx, J; Heykants, J; Hurkmans, R; Knaeps, F; Lauwers, W; Meuldermans, W; Swysen, E; Woestenborghs, R,
)
0.73
" A substantial first-pass effect led to a bioavailability of about 50% (range: 27-69%)."( Pharmacokinetics of ketanserin in man.
Klotz, U; Okonkwo, PO; Reimann, IW, 1983
)
0.59
" L-772,405 also shows very good selectivity over a range of other serotonin and nonserotonin receptors and has excellent bioavailability following subcutaneous administration in rats."( 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
Beer, MS; Broughton, HB; Castro, JL; Hitzel, L; Matassa, VG; Pengilley, RR; Russell, MG; Sohal, B; Stanton, JA; van Niel, MB; Watt, AP, 1999
)
0.3
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The bioavailability of 29 was significantly improved in comparison with its aglycon."( Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
Chen, C; Cheng, K; Dai, L; Hu, K; Li, H; Liu, L; Sun, H; Wen, X; Xu, Q; Yuan, H, 2021
)
0.62

Dosage Studied

Ketanserin and its analogues R56413 and ritanserin were studied. The QT interval (QTc) was significantly increased after 1 month's treatment. We conclude that therapeutic plasma levels can be obtained in pre-eclamptic patients.

ExcerptRelevanceReference
" Pretreatment with either prazosin (5 x 10(-9) - 10(-8) M) or ketanserin (5 x 10(-9) - 10(-8) M) leads to decreased slopes and Emax in the 2C-B dose-response curves."( The action of the psychoactive drug 2C-B on isolated rat thoracic aorta.
Borges, Y; Cassels, BK; Gonzalez, E; Lobos, M, 1992
)
0.52
" The 5-HT2 receptor antagonist ketanserin (1 microM) caused a clear rightward shift of the dose-response curve to 5-HT on the guinea-pig ganglion, but not on the mouse or rat ganglion."( Evidence that the 5-HT3 receptors of the rat, mouse and guinea-pig superior cervical ganglion may be different.
Cheshire, SH; Gilbert, MJ; Newberry, NR, 1991
)
0.57
" We have used dose-response curves to quantitate the potentiation of adenosine 5'-diphosphate (ADP)-induced aggregation and thromboxane (TXA2) generation by 5-hydroxytryptamine (5-HT) and adrenaline in human citrated platelet-rich plasma."( Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.
Bochner, F; Duncan, EM; Lloyd, JV; Rodgers, SE; Vanags, DM, 1992
)
0.28
" Indices of amplification were leftward shifts of methoxamine dose-response (DR) curves produced by 5-HT (0."( Evidence for a 5-HT1-like receptor mediating the amplifying action of 5-HT in the rabbit ear artery.
de la Lande, IS, 1992
)
0.28
" When milk intake was stable, dose-response functions were determined for cocaine (4."( Attenuation of the effects of cocaine on milk consumption in rats by dopamine antagonists.
Rapoza, D; Woolverton, WL, 1991
)
0.28
"A dosage regimen of lysergic acid diethylamide (LSD) that reliably produces behavioral tolerance in rats was evaluated for effects on neurotransmitter receptor binding in rat brain using a variety of radioligands selective for amine receptor subtypes."( Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin2 receptors in rat brain.
Buckholtz, NS; Freedman, DX; Potter, WZ; Zhou, DF, 1990
)
0.28
" However, LY 53857 differs from ketanserin in that it shifts the pressor dose-response curve to 5-HT in a parallel way at low doses but in a noncompetitive way at higher doses."( Comparison between ketanserin and LY 53857 on vascular and cardiac 5-HT2 and alpha 1-adrenergic receptors in the pithed rat.
Chaouche-Teyara, K; Cherqui, C; Dabiré, H; Fournier, B; Schmitt, H,
)
0.74
" Following long term oral dosing (20 or 40 mg twice daily) the pharmacokinetics remain linear and steady-state concentrations, which can be predicted from single-dose kinetics, are reached within 4 days."( Clinical pharmacokinetics of ketanserin.
Hedner, T; Heykants, J; Persson, B, 1991
)
0.57
" This specific type of pharmaceutical treatment appeared to be especially suitable for this disease owing to a combination of therapeutic efficacy and a substantial reduction in the total dosage for each patient."( Regional intravenous ketanserin and guanethidine therapy in Raynaud's phenomenon.
Caputi, CA; De Carolis, G; Tomasetti, C, 1991
)
0.6
" Rings of these vessels were mounted under isometric tension, and dose-response curves to 5-HT were obtained."( Alterations in serotonergic receptor expression in experimental vein grafts.
Hagen, PO; McCann, RL; Mikat, EM; O'Donohoe, MK; Radic, ZS; Schwartz, LB; Stein, AD, 1991
)
0.28
" These results suggest either a reduction in the oral dosage of ketanserin or an increase in the interval between doses in patients with cirrhosis."( Pharmacokinetics of ketanserin in patients with cirrhosis.
Benhamou, JP; Berthelot, P; Fraitag, B; Gaudin, C; Hadengue, A; Lebrec, D; Levron, JC, 1990
)
0.84
"In the spontaneously hypertensive rat (SHR), ketanserin and the ketanserin analogues R56413 and ritanserin were studied with regard to their ability to reduce the blood pressure in conscious rats and shift the dose-response curves for phenylephrine and serotonin (5-HT) in pithed rats after acute administration."( Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action.
Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1985
)
0.82
" The dose-response curve of blood pressure against rate of phenylephrine infusion was shifted to the right in keeping with alpha 1-adrenergic antagonism; the degree of shift was small compared with that after prazosin."( Ketanserin and alpha 1-adrenergic antagonism in humans.
Ball, SG; Robertson, JI; Zabludowski, JR, 1985
)
1.71
" Dosage in excess of 60 mg of Kn per day caused troublesome central nervous system symptoms or headache in some patients."( Clinical studies with ketanserin in hypertension.
Brown, SA; Simpson, FO; Spears, GF; Waal-Manning, HJ, 1985
)
0.58
" In vitro dose-response curves suggested that prolonged ketanserin intake results in a higher "sensitivity" of the platelets to serotonin rather than a refractoriness of the platelets to ketanserin."( Platelet hypersensitivity to serotonin after prolonged ketanserin intake?
Amery, A; Arnout, J; Deckmyn, H; Fiocchi, R; Lijnen, P; Van Russelt, M; Vermylen, J, 1985
)
0.76
" Bucindolol caused a parallel shift to the right of the dose-response curves for both serotonin (5-HT) and phenylephrine (PE), indicating competitive antagonism."( Bucindolol has serotonin and alpha-adrenoceptor blocking properties.
Marwood, JF; Stokes, GS, 1985
)
0.27
" produced a two-fold shift to the right of the dose-response curve of locally infused 5-hydroxytryptamine (5-HT) but increased only slightly the ED50 of locally infused pizotifen."( Pizotifen, an antimigraine drug with venoconstrictor activity in vivo.
Müller-Schweinitzer, E,
)
0.13
" The twice daily dosage schedule caused trough blood pressure control with both drugs."( Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial.
Alcocer, L; Copertari, P; Feruglio, F; Landi, E; Lopes, M; San Martin, C; Zin, C, 1987
)
0.54
"This study assesses the efficacy, safety, and dose-response curve of ketanserin, according to parenteral routes of administration, in the treatment of acute severe essential hypertension."( Ketanserin in parenteral treatment of acute essential hypertension: a dose-response curve.
Lemus, J; Lucioni, MC; Milei, J; Schiavone, M, 1987
)
1.95
" Whereas the blood pressure reduction to acute administration of ketanserin was directly related to its ability to shift the dose-response curve of phenylephrine (alpha 1-adrenergic blockade), the same relationship was not apparent following chronic treatment with ketanserin."( Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
Gradin, K; Hedner, T; Persson, B; Pettersson, A, 1988
)
0.81
" Cumulative dose-response curves were constructed for either cinanserin or 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in animals that had received a maximal hypotensive dose of prazosin that had, in addition to decreasing blood pressure, decreased heart rate and background activity in all three nerves."( Are drugs that act both on serotonin receptors and alpha 1-adrenoceptors more potent hypotensive agents than those that act only on alpha 1-adrenoceptors?
Ramage, AG, 1988
)
0.27
" After 6 weeks of ketanserin (40 mg every 12 h), blood pressures measured 12 h after dosing were not significantly different from those obtained during the placebo period."( Antihypertensive therapy with ketanserin: metabolic and hemodynamic effects.
Goldstein, DS; Keiser, HR; Levinson, PD; Zimlichman, R, 1988
)
0.9
" Both hypotensive agents shifted the dose-response curve to NE to the right."( Effect of ketanserin and prazosin on blood pressure and cardiovascular reactivity to vasopressor agents during the development of two kidney-two clip renal hypertension in the conscious rat.
Basso, N; Kurnjek, M; Mikulic, L; Taquini, AC, 1989
)
0.68
" BOL caused concentration-dependent parallel rightward shifts of the 5-HT dose-response curve in untreated aortas but, in addition, caused a marked reduction of maximal response in aortas pretreated with benextramine to inactivate alpha adrenoceptors."( Evidence for allosteric blockade of serotonergic receptors in rabbit thoracic aorta.
Purdy, RE; Xu, Z, 1989
)
0.28
"0 mg/kg MDA in both components of the multiple schedule, but did not affect the MDMA dose-response curve."( Behavioral effects of (+-) 3,4-methylenedioxyamphetamine (MDA) and (+-) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: interactions with noradrenergic and serotonergic systems.
Barrett, JE; Hoffmann, SM; Nader, MA, 1989
)
0.28
" Dose-response curves revealed that maximal hyperglycemia was associated with hypoinsulinemia."( 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat.
Chaouloff, F; Jeanrenaud, B, 1987
)
0.27
" The dose-response kinetics with four doses of bethanechol with and without somatostatin showed inhibition of a non-competitive type for gastric acid secretion and of a competitive type for antral motility with regard to amplitude."( Effect of somatostatin on bethanechol-stimulated gastric acid secretion and gastric antral motility in dogs with gastric fistula.
Andersen, D; Bech, K; Ladegaard, L, 1985
)
0.27
" The data in this study show that ketanserin as an antihypertensive agent is as effective as prazosin, but in contrast requires no titration of dosage and better compliance can be expected with twice daily rather than three times daily dosing."( Moderate essential hypertension control: a double-blind crossover study between a serotonin antagonist and a post-synaptic alpha-blocker.
Fisher, R; Gruebel, B; Koehle, W; Rosenthal, J, 1986
)
0.55
" An intraluminal injection of serotonin (5-HT) produced a marked vasoconstriction and the dose-response curve was bell-shaped."( Pharmacological analysis of 5-HT-induced vasoconstriction in isolated, perfused dog skeletal muscle arteries.
Chiba, S; Sinanović, O, 1987
)
0.27
" At a dosing regimen of KET that inhibited the 5-HT-induced platelet shape change in platelet-rich plasma and the 5-HT-induced increase in perfusion pressure in isolated lungs, KET did not affect the elevation in lung weight or the increased accumulation of 125I-albumin in the lung tissue of MCTP-treated rats."( Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
Ganey, PE; Hadley, KB; Roth, RA; Sprugel, KH, 1986
)
0.49
" In the intact animal it may cause increases or decreases of blood pressure and in isolated blood vessels contraction or relaxation depending on the species and vascular bed studied, the route of administration and the dosage used."( Serotonin and the blood vessel wall.
Lüscher, TF; Vanhoutte, PM, 1986
)
0.27
" After placebo dosing for 2 weeks, active drug was given double-blind in two 4-week phases."( Ketanserin and prazosin: a comparison of antihypertensive and biochemical effects.
Marwood, JF; Mennie, BA; Stokes, GS, 1986
)
1.71
" 5-HT agonists stimulated [3H]inositol phosphate accumulation in a dose-related but biphasic manner and only the high-affinity component of the dose-response curve was sensitive to antagonists."( 5-Hydroxytryptamine-stimulated inositol phospholipid hydrolysis in rat cerebral cortex slices: pharmacological characterization and effects of antidepressants.
Kendall, DA; Nahorski, SR, 1985
)
0.27
" In addition, lack of Ca2+ caused a shift to the right in the dose-response curve for phenylephrine-induced IP formation whereas serotonin-induced IP formation was not affected by changes in Ca2+e."( Influence of Ca2+e on 5-HT2- and alpha 1-induced arterial contraction and phosphoinositide metabolism.
Berta, P; Chevillard, C; Haiech, J; Mathieu, MN; Seguin, J; Vidal, N, 1986
)
0.27
" In humans, the drug has a terminal half-life of 12-25 hours, and a twice daily dosage will lower blood pressure over the day."( Effects of a new serotonin antagonist, ketanserin, in experimental and clinical hypertension.
Hedner, T; Persson, B, 1988
)
0.54
"01); twice daily dosage appeared satisfactory."( Ketanserin in essential hypertension: a double-blind, placebo-controlled study.
Cameron, HA; Ramsay, LE, 1985
)
1.71
" The excretion of the urinary and faecal metabolites after repeated dosing was very similar to that after a single dose."( Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
Geerts, R; Hendriks, R; Heykants, J; Meuldermans, W; Michiels, M; Monbaliu, J; Woestenborghs, R, 1988
)
0.54
" The QT interval (QTc) was significantly increased after 1 month's treatment: at 1 h after dosing 334 +/- 32 ms after 1 month of ketanserin compared with 302 +/- 31 ms after placebo."( Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.
Donnelly, R; Elliott, HL; Meredith, PA; Reid, JL, 1987
)
0.81
" Ketanserin, only at the concentration as high as 10(-4)M, produced slight rightward shift of the positive chronotropic but not inotropic dose-response curves for norepinephrine in guinea pig atria."( Cardiac effects of ketanserin, a serotonin antagonist--electrophysiological examinations as a part of toxicity studies.
Shigenobu, K; Tatsuno-Atoda, H, 1988
)
1.51
" After 6 weeks of ketanserin (40 mg every 12 hours), blood pressures measured 12 hours after dosing were not significantly different from those obtained after placebo."( Metabolic and hemodynamic effects of antihypertensive treatment with ketanserin.
Brewer, HB; Goldstein, DS; Keiser, HR; Levinson, PD; Zimlichman, R, 1988
)
0.84
"Two double-blind multicenter trials were performed to compare the antihypertensive action of ketanserin, at an oral dosage of 20 mg three times daily, with that of placebo over a period of four to six weeks."( Double-blind comparison of ketanserin with placebo in patients with essential hypertension.
Baeten, B; Peeters, G; Sieben, G; Symoens, J; Wellens, D, 1986
)
0.79
" Escherichia coli endotoxin (055-B5) was infused IV at a dosage of 5 micrograms/kg for 1 hour (group 2)."( Effects of ketanserin on pulmonary hemodynamics, lung mechanics, and gas exchange in endotoxemic pigs.
Anderson, DL; Grizzle, MK; Olson, NC, 1986
)
0.66
"The metabolic reduction-oxidation equilibrium between ketanserin and ketanserin-ol was studied after oral dosing of both substances to two healthy volunteers."( Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol.
Embrechts, L; Heykants, J; Van Peer, A; Woestenborghs, R, 1986
)
0.78
" Its effect on Raynaud's phenomenon was evaluated by IR-radiometry, Doppler ultrasound, nailfold capillaroscopy, frequency of finger ulcerations and patient complaints before and after a 3-month course of treatment with oral ketanserin in the dosage of 60 mg daily in the first month and 120 mg in the second and third months."( Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác, J; Rovenský, J; Tauchmannová, H; Zitnan, D, 1985
)
0.86
" In po dosed bile-cannulated rats, 57% was excreted with the bile within 24 hr, whereas about 30 to 40% of the biliary radioactivity was subjected to enterohepatic circulation."( Excretion and biotransformation of ketanserin after oral and intravenous administration in rats and dogs.
Hendrickx, J; Heykants, J; Hurkmans, R; Knaeps, F; Lauwers, W; Meuldermans, W; Swysen, E; Woestenborghs, R,
)
0.41
" (10 mg) do not affect the pressor dose-response curve to phenylephrine."( Antihypertensive properties of ketanserin (R 41 468).
Janssen, PA; Symoens, J; Van Nueten, JM; Vanhoutte, PM, 1983
)
0.55
" Agonist-antagonist interactions were studied by pretreating the vessels with methysergide, ketanserin and phentolamine and then establishing the dose-response curves to 5-HT or noradrenaline (NA)."( Tryptaminergic receptors in the bovine pulmonary vasculature: effects of ketanserin.
Eyre, P; Ogunbiyi, PO, 1984
)
0.72
"Ketanserin, a new 5-hydroxy-tryptamine antagonist, was given at three different dosage levels (double-blind, randomized) in a dose finding study for 2 months to 31 patients with mild to moderately severe essential hypertension."( Ketanserin in hypertension. Early clinical evaluation and dose finding study of a new 5-HT2 receptor antagonist.
Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Svensson, A, 1983
)
3.15
"Blood pressure and heart rate, supine and standing, were studied in patients with essential hypertension during 8 weeks of oral therapy with two dosage schedules of ketanserin, 40 mg once and twice daily."( Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.
Berglund, G; Hedner, T; Persson, B, 1983
)
1.9
") was administered at 30 min intervals on four experimental days: no pretreatment; after prazosin 1 mg/kg and infusion; after pharmacological 'total' autonomic effector block (TAB) and with repeated three point methoxamine dose-response lines."( Haemodynamic response to ketanserin in rabbits with Page hypertension: comparison with prazosin.
Angus, JA; Wright, CE, 1983
)
0.57
" After acquisition, the quipazine and ketanserin dose-response curves were found to be orderly and reproducible."( Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.
Barrett, RJ; Sanders-Bush, E; Smith, RL, 1995
)
0.81
" Dose-response analysis of receptor occupancy revealed risperidone demonstrated higher binding affinity for 5-HT2 than for D2, while the reverse was observed with haloperidol."( In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol.
Kido, H; Mori, H; Sakamoto, H; Shiba, K; Sumiyoshi, T; Suzuki, K; Urasaki, K; Yamaguchi, N; Yokogawa, K, 1994
)
0.29
" In both tissues, variations in perfusate [Ca2+] had similar effects: threshold contractile concentrations of 5-HT were unaffected, and the upper ends of the 5-HT dose-response curves were augmented or decreased by increased or decreased [Ca2+], respectively."( Interaction between Ca2+, verapamil, and ketanserin in rat tail artery and aorta.
Marwood, JF; Okoro, EO; Stokes, GS, 1995
)
0.56
" Methylene Blue (which blocks production of cGMP by EDRF-NO) and Nw-nitro-L-arginine (which inhibits EDRF-NO synthesis), both shifted 5-HT dose-response curves to the left and completely abolished the differences in sensitivity to the agonist."( Nitric oxide and superoxide anions in vascular reactivity of renovascular hypertensive rats.
Bellver, A; Celentano, MM; de la Riva, IJ; Rosón, MI; Vega, GW, 1995
)
0.29
"A cumulative dose-response curve of the effects of serotonin and its 5-HT2 receptor antagonist ketanserin in embryonic chick skin has been set up using morphological analysis and incorporation of 3H-thymidine as parameters."( Dose-response curve of the effects of serotonin and ketanserin on the functional morphology of skin in vitro.
Beele, H; de Ridder, L; Thierens, H, 1994
)
0.76
" dosage again displayed significant efficacy when administered at 15 min delaying treatment to 30 min resulted in only marginal therapeutic actions."( Characterization of mianserin neuroprotection in experimental spinal trauma: dose/route response and late treatment.
Agresta, CA; Azim, S; Chavin, J; Kelly, G; Puniak, MA; Salzman, SK; Wang, L, 1994
)
0.29
" The dose-response curve obtained with the 5-HT1 receptor agonist, 5-carboxamidotryptamine (5-CT), was biphasic in arteries with endothelium; removal of the endothelium eliminated the first phase of the contraction."( Endothelial thromboxane production plays a role in the contraction caused by 5-hydroxytryptamine in rat basilar arteries.
Descombes, JJ; Devys, M; Laubie, M; Verbeuren, TJ, 1993
)
0.29
" Combination therapy, involving 16 patients and both drugs given at the original dosage schedule for 12 weeks, resulted in further reductions in systolic and diastolic blood pressures, and an improvement in left ventricular function; indices of diastolic function were not modified."( Ketanserin alone and in combination with enalapril in the treatment of essential hypertension: assessment of the haemodynamic effects.
Assogna, G; Celentano, A; Crivaro, M; de Divitiis, O; Galderisi, M; Garofalo, M; Palmieri, V; Tammaro, P; Zanna, C,
)
1.57
" The dose-response curve for 5-HT was shifted 9-fold to the left compared to controls, and the Vmax value was also significantly enhanced."( Dexamethasone potentiates serotonin-2 receptor-mediated intracellular Ca2+ mobilization in C6 glioma cells.
Kagaya, A; Mikuni, M; Muraoka, S; Saitoh, K; Takahashi, K, 1993
)
0.29
" 5-Hydroxytryptamine and a small amount of the supernatant shifted the dose-response curves of collagen to the left."( Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits.
Takano, S,
)
0.13
"In a study on the dose-response relationship for longwave UVA (UVA1; 340-400 nm) carcinogenesis in hairless mice scratch marks appeared after months of daily exposure as an unwanted side effect."( Chronic UVA (365-nm) irradiation induced scratching in hairless mice: dose-time dependency and the effect of ketanserin.
de Gruijl, FR; de Laat, JM; Groenendijk, M; Seité, S; van Vloten, WA, 1997
)
0.51
"Ketanserin in this dosage is less effective to lower diastolic blood pressure."( Dihydralazine or ketanserin for severe hypertension in pregnancy? Preliminary results.
Odendaal, HJ; Steyn, DW, 1997
)
2.08
" Dose-response curves were obtained for the effects of several 5-HT2 receptor antagonists on response magnitude."( Effect of 5-HT2 receptor antagonists on a cranial nerve reflex in the rabbit: evidence for inverse agonism.
Harvey, JA; Hood, H; Romano, AG; Welsh, SE, 1999
)
0.3
" In an attempt to further clarify the mechanisms underlying these degeneration patterns, autoradiographic studies using a variety of receptor ligands were conducted in animals 21 days after an identical dosage of the continuous phencyclidine administration employed in the previous degeneration studies."( Long-term changes in brain following continuous phencyclidine administration: an autoradiographic study using flunitrazepam, ketanserin, mazindol, quinuclidinyl benzilate, piperidyl-3,4-3H(N)-TCP, and AMPA receptor ligands.
Ellison, G; Keys, A; Noguchi, K, 1999
)
0.51
" Five-day repeat dosing of a typical SSRI, paroxetine, increased climbing, a distinctive antidepressive behavior, 1 h after but not 1 h before treatment."( Effects of repeated selective serotonin reuptake inhibitor paroxetine treatments on mouse forced swimming.
Akagawa, Y; Hishikawa, Y; Maruyama, A; Masuda, Y; Shimizu, T, 1999
)
0.3
" The ability of (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT(2A) receptor agonist, and ketanserin, a 5-HT(2A) receptor antagonist, to either substitute for or block the discriminative-stimulus effects of cocaine, or to shift the cocaine dose-response curve, was evaluated."( Differential involvement of 5-HT(2A) receptors in the discriminative-stimulus effects of cocaine and methamphetamine.
Goldberg, SR; Justinova, Z; Kutkat, SW; Munzar, P, 2002
)
0.53
"To establish the optimal dosage of ketanserin in the treatment of severe hypertension in pregnancy."( The optimal dosage of ketanserin for patients with severe hypertension in pregnancy.
de Jeu, RM; Odendaal, HJ; Steyn, DW; van Geijn, HP; van Schie, DL, 2002
)
0.91
"Ketanserin appears to be an attractive medicine in the treatment of severe hypertension in pregnancy, but the optimal dosage could not be established."( The optimal dosage of ketanserin for patients with severe hypertension in pregnancy.
de Jeu, RM; Odendaal, HJ; Steyn, DW; van Geijn, HP; van Schie, DL, 2002
)
2.07
" There was no dose-response relationship with the agonist."( Maternal aggression in Wistar rats: effect of 5-HT2A/2C receptor agonist and antagonist microinjected into the dorsal periaqueductal gray matter and medial septum.
da Silva, SP; de Almeida, RM; de Oliveira, VP; Giovenardi, M; Stein, DJ, 2005
)
0.33
" Initially, we established a dose-response relationship for the acute and chronic haloperidol and DOI-induced HTR."( Effects of donepezil, nicotine and haloperidol on the central serotonergic system in mice: implications for Tourette's syndrome.
Hayslett, RL; Tizabi, Y, 2005
)
0.33
" We conclude that therapeutic plasma levels can be obtained in pre-eclamptic patients with a fixed dosage schedule of ketanserin and differences in antihypertensive responses within a pre-eclamptic population cannot be attributed to pharmacokinetic differences."( Population pharmacokinetics of ketanserin in pre-eclamptic patients and its association with antihypertensive response.
Hanff, LM; Steegers, EA; Visser, W; Vulto, AG, 2005
)
0.82
"Pre-eclamptic patients (n=47) with a gestational age (GA) between 21 and 32 weeks were treated with intravenous ketanserin in a maximum dosage of 14 mg/h, to obtain a diastolic blood pressure of 90 mmHg or below."( Insufficient efficacy of intravenous ketanserin in severe early-onset pre-eclampsia.
Hanff, LM; Hop, WC; Roofthooft, DW; Steegers, EA; Vermes, A; Visser, W; Vulto, AG,
)
0.62
"With a maximum intravenous dosage of ketanserin, target blood pressure was not achieved in 15 (32%) patients."( Insufficient efficacy of intravenous ketanserin in severe early-onset pre-eclampsia.
Hanff, LM; Hop, WC; Roofthooft, DW; Steegers, EA; Vermes, A; Visser, W; Vulto, AG,
)
0.68
"1 mg/kg/injection) functioned as a positive reinforcer with sigmoidal or biphasic dose-response functions."( Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys.
Wee, S; Woolverton, WL, 2006
)
0.33
" Animals in groups 4 and 8 were given both lidoflazine and ketanserin according to the dosing schedules above."( Preservation of the ischemic canine myocardium: a comparison of hypothermia, lidoflazine, and ketanserin.
Clark, NJ; McJames, SW; Pace, NL; Port, JD; Stanley, TH; Stockham, RJ, 1988
)
0.74
" The usual dosage of ketanserin in the treatment of hypertension or vasospastic diseases is 40 to 80 mg per day, in two divided doses."( [Blockade of 5-HT2 receptors as a mechanism of antihypertensive action of ketanserin].
Prostran, M,
)
0.68
" Also, a dose-response relationship was established between the dose of cyclosporin A and the brain uptake of [(123)I]R91150 in mice."( Effect of cyclosporin A administration on the biodistribution and multipinhole muSPECT imaging of [123I]R91150 in rodent brain.
Blanckaert, P; Burvenich, I; De Bruyne, S; De Vos, F; Moerman, L; Staelens, S; Wyffels, L, 2009
)
0.35
"1 mg/kg) each shifted the dose-response curves of DOM, 2C-T-7, and DPT rightward in a parallel manner."( Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses.
France, CP; Li, JX; Rice, KC, 2009
)
0.35
" The effects of the phenethylamine hallucinogen R(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) on head-twitch behavior were studied over a range of doses in the mouse, generating a characteristic biphasic dose-response curve."( Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.
Cohen, MS; Fantegrossi, WE; Henson, CM; Rice, KC; Simoneau, J; Woods, JH; Zimmerman, SM, 2010
)
0.36
" Non-parametric as well as parametric tests were used to analyze the effect of gestational age, birth weight, gender, various ketanserin factors (cumulative dosage, duration of therapy and last dosage rate), other maternal drug use and maternal diagnosis on the blood pressure of the neonate."( The effect of maternal ketanserin use on the circulation of the neonate: a prospective, observational study.
de Vries, NK; Morssink, LP; Schaafstra, L; van Roon, EN, 2012
)
0.9
" The last dosage rate as well as the mean dosage rate (cumulative dosage divided by duration of therapy in hours) were significantly higher in the group with hypotension (P=."( The effect of maternal ketanserin use on the circulation of the neonate: a prospective, observational study.
de Vries, NK; Morssink, LP; Schaafstra, L; van Roon, EN, 2012
)
0.69
" The risk of hypotension is associated with the last dosage rate of maternal ketanserin treatment and the co-existence of maternal HELLP syndrome."( The effect of maternal ketanserin use on the circulation of the neonate: a prospective, observational study.
de Vries, NK; Morssink, LP; Schaafstra, L; van Roon, EN, 2012
)
0.92
" Instead, selective serotonin 2A receptor (5HT(2A)R) antagonists ketanserin and MDL-11939 replicate the effect of SGAs, repressing the activity in WT mice at a dosage that fails to suppress the activity of Egr3(-/-) mice."( Reduced levels of serotonin 2A receptors underlie resistance of Egr3-deficient mice to locomotor suppression by clozapine.
Elizalde, DI; Gallitano, AL; González-Maeso, J; Ingram, WM; Janowski, SA; Kamel, CM; Kozlenkov, A; Levine, S; Lish, JR; Resnik, J; Shoker, J; Williams, AA, 2012
)
0.62
" Furthermore, 5-HT2 antagonist, ketanserin, markedly reduces the positive chronotropic effect of 5-HT in a dose-response manner."( Pharmacological and genetic identification of serotonin receptor subtypes on Drosophila larval heart and aorta.
Cooper, RL; Majeed, ZR; Stacy, A, 2014
)
0.69
" The main outcome measures were persistent severe hypertension (DBP>100mmHg>120min) despite maximum dosage of study medication and prolongation of pregnancy."( Ketanserin versus dihydralazine for the treatment of severe hypertension in early-onset preeclampsia: a double blind randomized controlled trial.
Bijvank, SW; Duvekot, JJ; Edens, MA; Hanff, LM; Roofthooft, DW; Steegers, EA; Visser, W; Vulto, AG, 2015
)
1.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
cardiovascular drugA drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume.
EC 3.4.21.26 (prolyl oligopeptidase) inhibitorAny EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
quinazolinesAny organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
piperidines
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Serotonin and anxiety-related events02
Serotonin and anxiety04

Protein Targets (88)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency25.11890.003245.467312,589.2998AID2517
acetylcholinesteraseHomo sapiens (human)Potency32.78600.002541.796015,848.9004AID1347395; AID1347398
dopamine D1 receptorHomo sapiens (human)Potency0.00730.00521.30228.1995AID624455
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.10590.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency18.99590.173734.304761.8120AID1346859
USP1 protein, partialHomo sapiens (human)Potency42.28410.031637.5844354.8130AID504865
SMAD family member 3Homo sapiens (human)Potency18.99590.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency16.78550.000714.592883.7951AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency39.81070.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency27.88220.000221.22318,912.5098AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.35480.011212.4002100.0000AID1030
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency30.90080.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency2.23240.001310.157742.8575AID1259253; AID1259255
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency28.27480.001530.607315,848.9004AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.21260.000229.305416,493.5996AID743069; AID743075; AID743079
GVesicular stomatitis virusPotency12.30180.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency4.36490.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency29.84700.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.79430.035520.977089.1251AID504332
activating transcription factor 6Homo sapiens (human)Potency26.83250.143427.612159.8106AID1159516
Histone H2A.xCricetulus griseus (Chinese hamster)Potency55.19650.039147.5451146.8240AID1224845
cytochrome P450 2C19 precursorHomo sapiens (human)Potency2.51190.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency3.98110.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency3.39080.02245.944922.3872AID488982; AID488983
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency20.18650.001815.663839.8107AID894
chromobox protein homolog 1Homo sapiens (human)Potency28.18380.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency3.54810.01789.637444.6684AID588834
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency4.25620.425612.059128.1838AID504536
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency2.51190.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency12.30180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency13.33320.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency3.98110.00638.235039.8107AID883
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency11.22020.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency19.01150.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.00350.00010.532610.0000AID1798075
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.00160.00040.629810.0000AID4791; AID4822; AID4826
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.01290.00020.667710.0000AID4755; AID5225; AID5233; AID5238; AID5272; AID5273; AID5293
D(2) dopamine receptorHomo sapiens (human)Ki0.12170.00000.651810.0000AID1798075; AID63973
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.00210.00040.908610.0000AID4791; AID4822; AID4826; AID5478
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00330.00010.601710.0000AID1278110; AID1297676; AID1365269; AID1798075; AID1855073; AID296885; AID302139; AID442988; AID5225; AID5233; AID5238; AID5272; AID5273; AID5293; AID5568; AID599610; AID633919
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01500.00021.874210.0000AID36869
DRattus norvegicus (Norway rat)Ki3.00000.00010.610010.0000AID61530
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)1.00000.00031.38338.4000AID4128; AID4135
D(4) dopamine receptorHomo sapiens (human)Ki0.00350.00000.436210.0000AID63537
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01500.00021.270410.0000AID36869
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki10.00000.00031.465610.0000AID1387460
5-hydroxytryptamine receptor 1DHomo sapiens (human)IC50 (µMol)3.51000.00050.28702.4000AID4513; AID4596; AID4599
5-hydroxytryptamine receptor 1BHomo sapiens (human)IC50 (µMol)8.25000.00050.39756.5000AID4511; AID4513
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.01840.00010.88018.8500AID1152649; AID1196371; AID1256394; AID1285657; AID1336356; AID1409506; AID1433980; AID1597291; AID1704737; AID340263; AID346453; AID352184; AID566272; AID750630; AID751834; AID752216
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.00160.00000.385510.0000AID1152682; AID1196328; AID1387457; AID1433980; AID1597291; AID1915710; AID346453; AID389734; AID389735; AID611934; AID697464; AID751834
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.00270.00011.03029.0000AID255315
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.07180.00010.954910.0000AID4747; AID5835
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki1.90000.00031.29679.2440AID4699
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.00160.00040.615610.0000AID4791; AID4822; AID4826
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.00680.00020.590910.0000AID5225; AID5233; AID5238; AID5272; AID5273; AID5293
Histamine H1 receptorCavia porcellus (domestic guinea pig)Ki0.01000.00261.783210.0000AID1855075
Sodium-dependent serotonin transporterHomo sapiens (human)Ki10.00000.00000.70488.1930AID1387459
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Ki0.00350.00000.14803.1800AID1798075
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki1.29650.00030.380610.0000AID1546005; AID6587
Histamine H1 receptorHomo sapiens (human)Ki0.00200.00000.511010.0000AID697463
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.29000.00011.18738.9125AID751648
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.18000.00030.769310.0000AID751648
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01500.00001.819410.0000AID36869
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.01000.00000.965010.0000AID1855076
5-hydroxytryptamine receptor 5AHomo sapiens (human)Ki20.00000.00080.94335.1600AID6479; AID6480
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki2.80000.00020.522910.0000AID6514
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)Ki0.00350.00050.00180.0035AID296885
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)1.80000.00010.54948.4000AID61545; AID64449
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.77700.00000.437510.0000AID1855074; AID6587
Synaptic vesicular amine transporterHomo sapiens (human)IC50 (µMol)0.18000.01320.48594.2000AID1387455
Synaptic vesicular amine transporterHomo sapiens (human)Ki0.54000.00530.83242.7600AID1387446; AID1387447; AID1387454
Vesicular acetylcholine transporterRattus norvegicus (Norway rat)Ki10.00000.00130.56224.5230AID674902
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.00100.00030.70285.3660AID203852
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 1AHomo sapiens (human)Kd0.79430.00010.95285.0119AID438555
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd0.00150.00042.58328.5114AID4847; AID5068
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd0.00150.00012.62198.5114AID4847; AID5068
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Kd0.01590.00020.52667.5858AID35868
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Kd0.01590.00020.89627.5858AID35868
5-hydroxytryptamine receptor 2AHomo sapiens (human)EC50 (µMol)0.00100.00000.22763.4750AID752104
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd0.00150.00042.47358.5114AID4847; AID5068
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Kd0.01590.00020.51397.5858AID35868
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2AHomo sapiens (human)Kb0.00200.00060.16891.1000AID1152674; AID1393516; AID1412489
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ke0.03200.03200.59730.8500AID513911
5-hydroxytryptamine receptor 2CHomo sapiens (human)Kb0.11200.00230.04150.1120AID1412491
5-hydroxytryptamine receptor 2BHomo sapiens (human)Kb1.98000.03100.69831.9800AID1412490
Histamine H2 receptorCavia porcellus (domestic guinea pig)K0.50.00180.00010.40364.8000AID88008
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (441)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of gamma-aminobutyric acid secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of serotonin secretion5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, GABAergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to cocaine5-hydroxytryptamine receptor 1BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1BHomo sapiens (human)
drinking behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to ethanol5-hydroxytryptamine receptor 1BHomo sapiens (human)
bone remodeling5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1BHomo sapiens (human)
response to mineralocorticoid5-hydroxytryptamine receptor 1BHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to alkaloid5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to xenobiotic stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration5-hydroxytryptamine receptor 1BHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation5-hydroxytryptamine receptor 1BHomo sapiens (human)
regulation of synaptic vesicle exocytosis5-hydroxytryptamine receptor 1BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1BHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
hippocampus development5-hydroxytryptamine receptor 5AHomo sapiens (human)
response to estradiol5-hydroxytryptamine receptor 5AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 5AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 5AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 5AHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
response to amphetamineSynaptic vesicular amine transporterHomo sapiens (human)
serotonin secretion by mast cellSynaptic vesicular amine transporterHomo sapiens (human)
histamine secretion by mast cellSynaptic vesicular amine transporterHomo sapiens (human)
neurotransmitter transportSynaptic vesicular amine transporterHomo sapiens (human)
chemical synaptic transmissionSynaptic vesicular amine transporterHomo sapiens (human)
locomotory behaviorSynaptic vesicular amine transporterHomo sapiens (human)
response to toxic substanceSynaptic vesicular amine transporterHomo sapiens (human)
post-embryonic developmentSynaptic vesicular amine transporterHomo sapiens (human)
monoamine transportSynaptic vesicular amine transporterHomo sapiens (human)
dopamine transportSynaptic vesicular amine transporterHomo sapiens (human)
sequestering of neurotransmitterSynaptic vesicular amine transporterHomo sapiens (human)
serotonin uptakeSynaptic vesicular amine transporterHomo sapiens (human)
histamine uptakeSynaptic vesicular amine transporterHomo sapiens (human)
neurotransmitter loading into synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
somato-dendritic dopamine secretionSynaptic vesicular amine transporterHomo sapiens (human)
proton transmembrane transportSynaptic vesicular amine transporterHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processSynaptic vesicular amine transporterHomo sapiens (human)
aminergic neurotransmitter loading into synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (116)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1BHomo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1BHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 5AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 5AHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein bindingSynaptic vesicular amine transporterHomo sapiens (human)
monoamine transmembrane transporter activitySynaptic vesicular amine transporterHomo sapiens (human)
monoamine:proton antiporter activitySynaptic vesicular amine transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySynaptic vesicular amine transporterHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (97)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
endoplasmic reticulum5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
calyx of Held5-hydroxytryptamine receptor 1BHomo sapiens (human)
serotonergic synapse5-hydroxytryptamine receptor 1BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 1BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1BHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
perikaryon5-hydroxytryptamine receptor 5AHomo sapiens (human)
postsynaptic specialization membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 5AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 5AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
centrosomeSynaptic vesicular amine transporterHomo sapiens (human)
plasma membraneSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicleSynaptic vesicular amine transporterHomo sapiens (human)
membraneSynaptic vesicular amine transporterHomo sapiens (human)
axonSynaptic vesicular amine transporterHomo sapiens (human)
dendriteSynaptic vesicular amine transporterHomo sapiens (human)
secretory granule membraneSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
intracellular membrane-bounded organelleSynaptic vesicular amine transporterHomo sapiens (human)
clathrin-sculpted monoamine transport vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
dopaminergic synapseSynaptic vesicular amine transporterHomo sapiens (human)
terminal boutonSynaptic vesicular amine transporterHomo sapiens (human)
synaptic vesicle membraneSynaptic vesicular amine transporterHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (384)

Assay IDTitleYearJournalArticle
AID1345075Human Vesicular monoamine transporter 1 (SLC18 family of vesicular amine transporters)1996Proceedings of the National Academy of Sciences of the United States of America, May-14, Volume: 93, Issue:10
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.
AID624222Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Nov-05, Volume: 268, Issue:31
Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase.
AID1345879Human D5 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1346000Human alpha1B-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B1996Life sciences, , Volume: 59, Issue:15
A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B1998Naunyn-Schmiedeberg's archives of pharmacology, Jan, Volume: 357, Issue:1
[3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)1999Journal of neurochemistry, May, Volume: 72, Issue:5
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
AID624228Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2B1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
AID1345971Human alpha1D-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID624231Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D1996Molecular pharmacology, Dec, Volume: 50, Issue:6
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID1346302Mouse 5-HT1B receptor (5-Hydroxytryptamine receptors)1992Proceedings of the National Academy of Sciences of the United States of America, Apr-01, Volume: 89, Issue:7
Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2003Life sciences, May-30, Volume: 73, Issue:2
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
AID624222Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A2000Molecular pharmacology, Nov, Volume: 58, Issue:5
Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1997Naunyn-Schmiedeberg's archives of pharmacology, Sep, Volume: 356, Issue:3
Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)2001Naunyn-Schmiedeberg's archives of pharmacology, Jun, Volume: 363, Issue:6
The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution.
AID1345068Human 5-HT5A receptor (5-Hydroxytryptamine receptors)1994FEBS letters, Dec-05, Volume: 355, Issue:3
Cloning and characterisation of the human 5-HT5A serotonin receptor.
AID624231Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1D1997Naunyn-Schmiedeberg's archives of pharmacology, Sep, Volume: 356, Issue:3
Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist.
AID1345908Human alpha1A-adrenoceptor (Adrenoceptors)2001Japanese journal of pharmacology, Jun, Volume: 86, Issue:2
Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B1994Molecular pharmacology, Aug, Volume: 46, Issue:2
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
AID1346903Rat 5-HT2B receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)1996Life sciences, , Volume: 59, Issue:15
A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines.
AID624215Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A1992The Biochemical journal, Aug-01, Volume: 285 ( Pt 3)High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1997Naunyn-Schmiedeberg's archives of pharmacology, Sep, Volume: 356, Issue:3
Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D/1B receptor antagonist.
AID1346919Rat 5-HT2A receptor (5-Hydroxytryptamine receptors)1998The Journal of pharmacology and experimental therapeutics, Jul, Volume: 286, Issue:1
Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B2003Life sciences, May-30, Volume: 73, Issue:2
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
AID1346919Rat 5-HT2A receptor (5-Hydroxytryptamine receptors)2000Molecular pharmacology, Nov, Volume: 58, Issue:5
Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2003Life sciences, May-30, Volume: 73, Issue:2
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)1997British journal of pharmacology, Sep, Volume: 122, Issue:1
Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b).
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)1996Life sciences, , Volume: 59, Issue:15
A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Aug-25, Volume: 268, Issue:24
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)1998British journal of pharmacology, Jul, Volume: 124, Issue:6
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1998British journal of pharmacology, Apr, Volume: 123, Issue:8
Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)1994Molecular pharmacology, Aug, Volume: 46, Issue:2
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2003Life sciences, May-30, Volume: 73, Issue:2
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1996Molecular pharmacology, Dec, Volume: 50, Issue:6
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
AID1345215Mouse 5-HT7 receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Aug, Volume: 44, Issue:2
Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1992The Biochemical journal, Aug-01, Volume: 285 ( Pt 3)High-level stable expression of recombinant 5-HT1A 5-hydroxytryptamine receptors in Chinese hamster ovary cells.
AID1345057Human Vesicular monoamine transporter 2 (SLC18 family of vesicular amine transporters)1996Proceedings of the National Academy of Sciences of the United States of America, May-14, Volume: 93, Issue:10
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
AID1345718Human D1 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)1996Life sciences, , Volume: 59, Issue:15
A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines.
AID1739737Metabolic stability in ICR/CD-1 mouse liver microsomes assessed as half life preincubated for 5 mins followed by NADPH addition and measured up to 45 mins by LC/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I.
AID1915710Antagonist activity at 5-HT2A (unknown origin) assessed as inhibition constant2021European journal of medicinal chemistry, Feb-05, Volume: 211Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
AID4513Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID699060Antagonist activity at human 5HT7A receptor expressed in human HeLa cells assessed as inhibition of forskolin-induced cAMP accumulation by ELISA2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo.
AID1409505Antagonist activity at serotonin 5-HT2A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of serotonin-induced calcium flux at 10 uM after 15 mins by calcium 4-dye based FLIPR assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
AID5812Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID5068In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID1637990Intrinsic clearance in mouse liver microsomes in presence of NADPH by LC-MS analysis
AID5098Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
[125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors.
AID1637989Intrinsic clearance in rat liver microsomes in presence of NADPH by LC-MS analysis
AID1900027Hepatic extraction ratio in rat liver microsomes at 1 uM incubated for 45 mins in presence of NADPH by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID1442360Displacement of [3H]DOI-HCL from 5HT2A in Sprague-Dawley rat frontal cortex membranes measured after 20 mins2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID1546005Displacement of [3H]5-HT from recombinant human 5-HT7 receptor expressed in African green monkey COS7 cells2019European journal of medicinal chemistry, Dec-01, Volume: 183Structure-activity relationships of serotonin 5-HT
AID513911Binding affinity to 5HT2A2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies.
AID1855075Binding affinity to guinea pig cerebellum homogenate membrane H1 receptor incubated for 30 mins2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
AID1728081Metabolic stability in mouse liver microsomes assessed as intrinsic clearance in presence of NADPH by LC-MS analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
AID1637986Half life in rat liver microsomes in presence of NADPH by LC-MS analysis
AID4511Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID232235Selectivity ratio for 5-HT1C compared to 5-HT2 receptors.1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding.
AID1196328Displacement of [3H]ketanserin from human 5-HT2A receptor expressed in HEK-293 cells2015European journal of medicinal chemistry, Mar-06, Volume: 92Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID1816862Metabolic stability in human liver microsomes assessed as half life at 1 uM measured upto 45 mins in presence of NADPH by LC/MS/MS analysis2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection.
AID177864Inhibition of 5-HT induced pressor response in pithed rats, after intravenous administration, activity is expressed as ED501988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID751834Binding affinity to human 5-HT2A receptor by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID4747Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID1666048Half life in human liver microsomes at 1 uM in presence of NADPH by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor.
AID1412493Selectivity ratio of Kb for human 5-HT2C receptor to Kb for human 5-HT2A receptor2018MedChemComm, Mar-01, Volume: 9, Issue:3
Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
AID172549Inhibition of phenylephrine induced pressor response in pithed rats (following i.v. administration of 0.31 mg/kg)1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID1387456Inhibition of VMAT2 in C57Bl/6J mouse striatal membranes assessed as reduction in [3H[-5HT uptake pre-incubated for 10 mins before [3H[-5HT addition and measured after 8 mins2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1905970Metabolic stability in rat liver microsomes assessed as half life at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Structure-Based Discovery and Optimization of Furo[3,2-
AID750630Antagonist activity at 5HT2A receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 assessed as inhibition of agonist-induced response incubated for 60 mins in incubator followed by 15 mins at room temperature by FLIPR assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1911188Stability in rat liver microsomes assessed as intrinsic clearance at 1.5 uM measured upto 90 mins in presence of NADPH by LC/MS analysis
AID221606The inhibition of compound was measured for 5 min in head twitches of mice induced by 5-HTP(100 mg/kg, ip) at the dose of 3 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID5094Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
[125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors.
AID1911187Stability in human liver microsomes assessed as intrinsic clearance at 1.5 uM measured upto 90 mins in presence of NADPH by LC/MS analysis
AID4596Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID5065Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand1996Journal of medicinal chemistry, Aug-02, Volume: 39, Issue:16
1-aryl-4-[(1-tetralinyl)alkyl]piperazines: alkylamido and alkylamino derivatives. Synthesis, 5-HT1A receptor affinity, and selectivity. 3.
AID1412494Selectivity ratio of Kb for human 5-HT2B receptor to Kb for human 5-HT2C receptor2018MedChemComm, Mar-01, Volume: 9, Issue:3
Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
AID221603The inhibition of compound was measured for 5 min in head twitches of mice induced by 5-HTP(100 mg/kg, ip) at the dose of 10 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1278110Displacement of [3H]ketanserin from 5HT2A receptor in Sprague-Dawley rat brain cortex incubated for 15 mins by liquid scintillation counting analysis2016European journal of medicinal chemistry, Mar-03, Volume: 110Synthesis, in vitro and in vivo pharmacological evaluation of serotoninergic ligands containing an isonicotinic nucleus.
AID1256395Antagonist activity at adrenergic alpha1A receptor (unknown origin)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor.
AID64449Inhibition of [3H]spiperone binding to Dopamine receptor D2 from rat striatal membranes1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID646439Antidepressant activity in ip dosed Swiss albino mouse assessed as inhibition of DOI-induced head twitches administered 20 mins before DOI challenge measured for 20 mins2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation.
AID1888641Intrinsic clearance in rat liver microsomes at 1 uM by LC-MS/MS analysis
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID4847Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
In vitro labeling of serotonin-S2 receptors: synthesis and binding characteristics of [3H]-7-aminoketanserin.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1739738Metabolic stability in ICR/CD-1 mouse liver microsomes assessed as intrinsic clearance preincubated for 5 mins followed by NADPH addition and measured up to 45 mins by LC/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID195207The compound was evaluated for the percentage inhibition in rat aorta stimulated with 30 uM 5-HT and tested at fixed concentration of 10 uM1994Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9
Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties.
AID6587Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID453206Toxicity in rat at 1 mg/kg, ip after 15 mins2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
AID1297676Displacement of [3H]ketanserin from 5HT2A receptor in Sprague-Dawley rat brain cortex incubated for 15 mins2016European journal of medicinal chemistry, Jun-30, Volume: 1165-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives.
AID1412491Antagonist activity at human 5-HT2C receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced receptor activation preincubated for 15 mins followed by serotonin addition and measured after 1 hr by TGFalpha shedding assay2018MedChemComm, Mar-01, Volume: 9, Issue:3
Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
AID225833compound was tested for antagonistic activity against 5-Hydroxytryptamine-induced head shake in mouse after intraperitoneal administration; Value ranges from 0.02-0.91987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and 5-hydroxytryptamine antagonist activity of 2-[[2-(dimethylamino)ethyl]thio]-3-phenylquinoline and its analogues.
AID1152682Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in HEK293 cells2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID1409506Antagonist activity at serotonin 5-HT2A receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of serotonin-induced calcium flux after 15 mins by calcium 4-dye based FLIPR assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
AID750632Antagonist activity at 5HT2A receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 assessed as inhibition of agonist-induced response at 10 uM incubated for 60 mins in incubator followed by 15 mins at room temperature by FLIPR assay rel2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
AID1779089Half life in rat liver microsomes2021European journal of medicinal chemistry, Oct-05, Volume: 221Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
AID346453Displacement of radiolabeled ketanserin from human 5HT2A receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID1393516Antagonist activity at human 5-HT2AR expressed in HEK293 cells assessed as inhibition of serotonin-induced IP1 accumulation after 60 mins by HTRF method
AID5272Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID453205Inhibition of MDMA-induced behavioral suppression in rat assessed as earning of 20 food pellets at 0.3 mg/kg, ip administered 15 mins before MDMA challenge by food-reinforced operant task method2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
AID5099Hill coefficient of compound was determined1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
[125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors.
AID1900020Half life in rat liver microsomes at 1 uM incubated for 45 mins in presence of NADPH by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID389734Displacement of [3H]ketanserin from 5HT2A receptor expressed in NIH3T3 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation.
AID1387454Displacement of [3H](+)-syn-Ethyl 1-(2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl)ethyl)-4-(4-fluorophenyl)piperidine-3-carboxylate from human VMAT2 expressed in HEK293 cell membranes incubated for 60 mins by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID4791Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Development of a receptor-interaction model for serotonin 5-HT2 receptor antagonists. Predicting selectivity with respect to dopamine D2 receptors.
AID1387460Displacement of [125I]RTI-55 from human NET expressed in HEK293 cell membranes2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID19560Hill coefficient of the compound1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
AID337897Displacement of [3H]5HT from 5HT1 receptor1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID1278101Antagonist activity at 5HT2A receptor in Sprague-Dawley rat ileum assessed as reduction in 5-HT-induced contraction at 0.1 uM incubated for 10 mins2016European journal of medicinal chemistry, Mar-03, Volume: 110Synthesis, in vitro and in vivo pharmacological evaluation of serotoninergic ligands containing an isonicotinic nucleus.
AID218677In vivo inhibitory activity in rats against elevation of blood pressure caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor after 1 hr of oral administration at the dose of 3 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID1412492Selectivity ratio of Kb for human 5-HT2B receptor to Kb for human 5-HT2A receptor2018MedChemComm, Mar-01, Volume: 9, Issue:3
Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
AID1816863Metabolic stability in human liver microsomes assessed as intrinsic clearance at 1 uM measured upto 45 mins in presence of NADPH by LC/MS/MS analysis2021Journal of medicinal chemistry, 05-27, Volume: 64, Issue:10
Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection.
AID5305Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
N-[1-(2-Phenylethyl)pyrrolidin-3-yl]-1-adamantanecarboxamides as novel 5-HT2 receptor antagonists.
AID232943Binding selectivity for 5-HT 1D/1B receptors1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype.
AID1613983Cytotoxicity against human T cells assessed as cell death at 1 to 10 uM measured after 24 hrs propidium iodide staining based flow cytometry2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
AID1905976Metabolic stability in human hepatocytes assessed as hepatic extraction ratio at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Structure-Based Discovery and Optimization of Furo[3,2-
AID5273Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID1904268Metabolic stability in mouse liver microsomes assessed as clearance2022Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9
Discovery of Novel Sertraline Derivatives as Potent Anti-
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1739735Metabolic stability in human liver microsomes assessed as intrinsic clearance preincubated for 5 mins followed by NADPH addition and measured up to 45 mins by LC/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I.
AID1613981Inhibition of DGKalpha in PHA-induced human Jurkat cells harboring SAP ShRNA assessed as restoration of restimulation-induced cell death at 1 uM measured after 24 hrs by trypan blue exclusion method2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
AID5596Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
AID1387446Displacement of [3H]reserpine from human VMAT2 expressed in HEK293 cell membranes incubated for 60 mins by scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1905971Metabolic stability in human liver microsomes assessed as half life at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Structure-Based Discovery and Optimization of Furo[3,2-
AID221609The inhibition of compound was measured for 8 min in head twitches of mice induced by 5-HTP(100 mg/kg, ip) at the dose of 1 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID196755Compound was evaluated for its activity at solubilized receptor (CHAPS/salt-solubilized preparation) from rat frontal cortex1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
In vitro labeling of serotonin-S2 receptors: synthesis and binding characteristics of [3H]-7-aminoketanserin.
AID1297689Inhibition of (+/-)DOI-induced head twitch response in Albino Swiss mouse at 5 mg/kg, ip administered 60 mins before (+/-)DOI injection measured for 20 mins relative to untreated control2016European journal of medicinal chemistry, Jun-30, Volume: 1165-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives.
AID1613984Inhibition of DGKalpha in OKT3-induced human T cells harboring SAP SiRNA assessed as restoration of restimulation-induced cell death at 1 to 10 uM preincubated for 30 mins followed by OKT3 stimulation and measured 24 hrs post dose by propidium iodide stai2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
AID442988Displacement of [3H]ketanserin from 5HT2A in Sprague-Dawley rat brain cortex by liquid scintillation counting2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Efficient microwave combinatorial synthesis of novel indolic arylpiperazine derivatives as serotoninergic ligands.
AID189203Percent reduction of blood pressure in spontaneously hypertensive rat after 10 min at intraperitoneal administration of 5 mg/kg1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID1611135Half life in human liver microsomes at 1 uM preincubated for 5 mins followed by NADPH addition and measured for 45 mins by LC/MS analysis2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Synthesis of analogs of the Gwt1 inhibitor manogepix (APX001A) and in vitro evaluation against Cryptococcus spp.
AID1855076Binding affinity to rat forebrain homogenate membrane alpha 1 adrenergic receptor incubated for 10 mins2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
AID633919Displacement of [3H]ketanserin from Sprague-Dawley rat brain cortex serotonin 5-HT2A receptor after 15 mins by liquid scintillation counting2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
New potent 5-HT(2A) receptor ligands containing an N'-cyanopicolinamidine nucleus: Synthesis and in vitro pharmacological evaluation.
AID1365280Antagonist activity at 5-HT2A receptor in Sprague-Dawley rat ielum assessed as reduction in 5-HT-evoked contraction at 0.1 uM2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
New 5-HT
AID5313In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID196754Compound was evaluated for its activity at membrane-bound receptor (M+L+P fraction) from rat frontal cortex1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
In vitro labeling of serotonin-S2 receptors: synthesis and binding characteristics of [3H]-7-aminoketanserin.
AID4110Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity.
AID1739734Metabolic stability in human liver microsomes assessed as half life preincubated for 5 mins followed by NADPH addition and measured up to 45 mins by LC/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I.
AID5072Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and 5-hydroxytryptamine antagonist activity of 2-[[2-(dimethylamino)ethyl]thio]-3-phenylquinoline and its analogues.
AID352184Antagonist activity at human 5HT2A receptor expressed in EC80 serotonin-stimulated CHOK1 cells by calcium mobilization assay2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
(+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners.
AID35868In vitro antagonistic activity tested against the contraction induced by phenylephrine through Alpha-1 adrenergic receptor in rat thoracic aortic strips1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID4869The compound was tested for binding affinity against 5-HT1D receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID3701Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and 5-hydroxytryptamine antagonist activity of 2-[[2-(dimethylamino)ethyl]thio]-3-phenylquinoline and its analogues.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID4699Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1911186Stability in rat liver microsomes assessed as half life at 1.5 uM measured upto 90 mins in presence of NADPH by LC/MS analysis
AID1597291Displacement of [3H] ketanserin from human recombinant 5-HT2A receptor measured after 60 mins by scintillation counter method
AID4822In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
High affinity and selectivity on 5-HT1A receptor of 1-aryl-4-[1-tetralin)alkyl]piperazines. 2.
AID4755Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1905973Metabolic stability in rat liver microsomes assessed as intrinsic clearance at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Structure-Based Discovery and Optimization of Furo[3,2-
AID196752Compound was evaluated for its activity at membrane-bound receptor (M+L+P fraction) from rat frontal cortex1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
In vitro labeling of serotonin-S2 receptors: synthesis and binding characteristics of [3H]-7-aminoketanserin.
AID1433980Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor in HEK293 cells after 60 mins by scintillation counting2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Pyrimidine-Based Inhibitors of Dynamin I GTPase Activity: Competitive Inhibition at the Pleckstrin Homology Domain.
AID5478Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand1996Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25
Structure-activity relationship studies on the 5-HT(1A) receptor affinity of 1-phenyl-4-[omega-(alpha- or beta-tetralinyl)alkyl]piperazines. 4.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID6514Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID1911185Stability in human liver microsomes assessed as half life at 1.5 uM measured upto 90 mins in presence of NADPH by LC/MS analysis
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID751648Displacement of [3H]Lysergic acid from human recombinant 5HT2B receptor expressed in CHOK1 cells after 60 mins2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1855074Binding affinity to rat striatum homogenate membrane D2 receptor incubated for 10 mins2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
AID1613978Antagonist activity at serotonin receptor in human PBMC assessed as inhibition of PMA-stimulated superoxide anion generation at 10 uM preincubated for 1 hr followed by PMA-stimulation and measured after 30 mins by spectrophotometric method2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
AID225616compound was tested for antagonistic activity against fenfluramine induced hyperthermia in rat after peroral administration 0.02-0.31987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Synthesis and 5-hydroxytryptamine antagonist activity of 2-[[2-(dimethylamino)ethyl]thio]-3-phenylquinoline and its analogues.
AID343052Antagonist activity at serotonin 5HT2A receptor assessed as effect on 5HT-induced isometric contractile force in isolated rings of pig coronary artery2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID36869Inhibition of [3H]prazosin binding to alpha-1 adrenergic receptor from rat cortical membranes1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID5603Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
AID1336356Displacement of [3H]ketanserin from human recombinant 5HT2A receptor expressed in HEK293 cells measured after 60 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID5568Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity.
AID1613982Effect on TCR signaling in OKT3-induced human T-cells harboring SiRNA assessed as restoration of restimulation-induced cell death at 1 to 10 uM preincubated for 30 mins followed by OKT3 stimulation and measured 24 hrs post dose by propidium iodide stainin2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
AID1739733Metabolic stability in human liver microsomes assessed as compound remaining preincubated for 5 mins followed by NADPH addition and measured up to 45 mins by LC/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I.
AID340263Inhibition of human 5HT2A receptor2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
AID419436Lipophilicity, log P of the compound2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and evaluation of 1-(quinoliloxypropyl)-4-aryl piperazines for atypical antipsychotic effect.
AID1285657Displacement of [3H]ketanserin from human recombinant 5-HT2A receptor expressed in HEK293 cells2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID1256394Antagonist activity at human 5-HT2A receptor assessed as inhibition of 5-HT-mediated internal calcium mobilization by FLIPR assay2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor.
AID697464Antagonist activity at 5HT2A receptor2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
AID611934Displacement of [3H]ketanserin from human 5HT2A receptor2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
AID1387462Cytotoxicity in HEK293 cells expressing human VMAT2 assessed as reduction in cell viability at 10 uM incubated for 24 hrs by MTT assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID1152649Antagonist activity at human recombinant 5-HT2A receptor assessed as inhibition of serotonin-induced inositol phosphate accumulation2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID302139Displacement of [3H]ketanserin from 5HT2A receptor in rat cortex membrane2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
1-Aminocyclopentane-1,2,4-tricarboxylic acids screening on glutamatergic and serotonergic systems.
AID1387459Displacement of [125I]RTI-55 from human SERT expressed in HEK293 cell membranes2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID5226Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID16721Biodistribution in rat cortex at 3 hr after dose administration.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Resolution and in vitro and initial in vivo evaluation of isomers of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate: a high-affinity ligand for the muscarinic receptor.
AID88008Displacement of [3H](-)-trans-H2-PAT from Guinea pig histamine H2 receptors.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors.
AID5598Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
AID196753Compound was evaluated for its activity at solubilized receptor (CHAPS/salt-solubilized preparation) from rat frontal cortex1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
In vitro labeling of serotonin-S2 receptors: synthesis and binding characteristics of [3H]-7-aminoketanserin.
AID1442361Displacement of [3H]ketanserin from 5HT2A in Sprague-Dawley rat frontal cortex membranes measured after 20 mins2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID180306Inhibitory concentration against phenylephrine in conscious spontaneously hypersensitive rats (SHR)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Studies on quinazolines. 5. 2,3-dihydroimidazo[1,2-c]quinazoline derivatives: a novel class of potent and selective alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID1779090Intrinsic clearance in rat2021European journal of medicinal chemistry, Oct-05, Volume: 221Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.
AID4599Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
AID165603In vitro anti-platelet activity was determined by the inhibition of 5-HT plus collagen-induced platelet aggregation of rabbit platelet-rich plasma2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
N-[1-(2-Phenylethyl)pyrrolidin-3-yl]-1-adamantanecarboxamides as novel 5-HT2 receptor antagonists.
AID194605In vivo inhibitory activity in rats against elevation of blood pressure caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor after 3h of oral administration at the dose of 3 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID1888638Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM measured after 30 mins by LC-MS/MS analysis
AID218678In vivo inhibitory activity in rats against elevation of blood pressure caused by phenylephrine (30 ug/kg, iv) through alpha-1 receptor after 1 hr of oral administration at the dose of 10 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID1899994Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM incubated for 45 mins in presence of NADPH by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID1728080Metabolic stability in human liver microsomes assessed as intrinsic clearance in presence of NADPH by LC-MS analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
AID230116Ratio of phenylephrine ED50/ 5-HT ED501988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID221607The inhibition of compound was measured for 8 min in head twitches of mice induced by 5-HTP(100 mg/kg, ip) at the dose of 0.1 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID773791Displacement of [3H]ketanserin from 5-HT2A receptor in Sprague-Dawley rat frontal cortex after 15 mins2013Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20
New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo.
AID61530In vitro binding affinity towards dDopamine receptor D1 by displacing [125I]FISCH radioligand in rat striatal homogenate1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
(+/-)-7-chloro-8-hydroxy-1-(4'-[125I]iodophenyl)-3-methyl-2,3,4,5- tetrahydro-1H-3-benzazepine: a potential CNS D-1 dopamine receptor imaging agent.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID203852The compound was tested for affinity towards sigma-3 receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.
AID1905975Metabolic stability in human hepatocytes assessed as hepatic clearance at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Structure-Based Discovery and Optimization of Furo[3,2-
AID599610Binding affinity to 5HT2A receptor in Sprague-Dawley rat frontal cortical homogenates after 15 mins2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents.
AID1888637Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM measured after 15 mins by LC-MS/MS analysis
AID1704737Antagonist activity at human 5HT2A receptor expressed in CHO-K1 cells assessed as inhibition of 5HT-induced calcium flux incubated for 60 mins at 37 degC followed by 15 mins incubation at room temperature and subsequent 5HT addition by calcium 4 dye based
AID5331Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
AID4826Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID1387447Displacement of [3H]DHTB from human VMAT2 expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting method2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID438555Binding affinity to 5HT1A receptor2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Physical binding pocket induction for affinity prediction.
AID5095Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
[125I]-1-(2,5-dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high-affinity state of 5-HT2 serotonin receptors.
AID751713Displacement of [3H]Lysergic acid from human recombinant 5HT2B receptor expressed in CHOK1 cells at 10 uM after 60 mins relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1666049Intrinsic clearance in human liver microsomes at 1 uM in presence of NADPH by LC-MS/MS analysis2020Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor.
AID1904267Metabolic stability in mouse liver microsomes assessed as half life2022Journal of medicinal chemistry, 05-12, Volume: 65, Issue:9
Discovery of Novel Sertraline Derivatives as Potent Anti-
AID1196371Antagonist activity against human recombinant 5-HT2A receptor expressed in CHOK1 cells assessed as reduction in alpha-methylserotonin-induced increase in intracellular Ca2+ levels by aequorin based radiometric and luminescence plate counting method2015European journal of medicinal chemistry, Mar-06, Volume: 92Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
AID61545Binding affinity at dopamine D2 receptor by [3H]spiperone displacement.1994Journal of medicinal chemistry, Apr-01, Volume: 37, Issue:7
Development of a receptor-interaction model for serotonin 5-HT2 receptor antagonists. Predicting selectivity with respect to dopamine D2 receptors.
AID16728Biodistribution in rat heart at 3 hr after dose administration.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Resolution and in vitro and initial in vivo evaluation of isomers of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate: a high-affinity ligand for the muscarinic receptor.
AID5835Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
AID5293Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor1996Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21
Novel potent sigma 1 ligands: N-[omega-(tetralin-1-yl)alkyl]piperidine derivatives.
AID6480Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID177876Inhibition of L-5-HTP (L-5-hydroxytryptophan) induced head twitches in rat1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID389735Displacement of [3H]ketanserein from 5HT2A receptor F340L mutant expressed in NIH3T3 cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Potential modes of interaction of 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives with the 5-HT2A receptor: a ligand structure-affinity relationship, receptor mutagenesis and receptor modeling investigation.
AID1365269Displacement of [3H]ketanserin from serotonin 5-HT2A receptor in Sprague-Dawley rat brain cortex homogenates incubated for 15 mins by liquid scintillation spectrometry2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
New 5-HT
AID233583Ratio of IC50 for human 5-HT1B to human 5-HT1D receptors1999Journal of medicinal chemistry, Dec-02, Volume: 42, Issue:24
3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists.
AID130902Inhibition of methyl phenidate induced stereotyped gnawing in mice1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID337898Displacement of [3H]ketanserin from 5HT2 receptor1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID1888592Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM measured after 5 mins by LC-MS/MS analysis
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID5233Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarboxamides as selective 5-HT1A receptor agonists.
AID35710In vivo inhibitory activity in rats against elevation of blood pressure caused by phenylephrine (30 ug/kg, iv) through Alpha-1 adrenergic receptor, after 1 hr oral administration at dose of 10 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID1637985Half life in human liver microsomes in presence of NADPH by LC-MS analysis
AID1637988Intrinsic clearance in human liver microsomes in presence of NADPH by LC-MS analysis
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID65751Competitive binding assay against Dopamine receptor D2 in rat striatal membranes and [125I]-IBF radioligand1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.
AID1412490Antagonist activity at human 5-HT2B receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced receptor activation preincubated for 15 mins followed by serotonin addition and measured after 1 hr by TGFalpha shedding assay2018MedChemComm, Mar-01, Volume: 9, Issue:3
Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
AID5452The compound was tested for binding affinity against 5-HT2A receptor1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
AID113360In vivo effective dose required for inhibiting (+/-)-DOI-induced (2.5 mg/kg, ip) twitches in mice2001Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9
Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity.
AID33557The ability concentration.)2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
AID697463Antagonist activity at histamine H1 receptor2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
AID674902Displacement of [125I]O-iodo-trans-decalinvesamicol from VAChT in Sprague-Dawley rat cerebral membrane after 1 hr by gamma counting2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
Syntheses and in vitro evaluation of decalinvesamicol analogues as potential imaging probes for vesicular acetylcholine transporter (VAChT).
AID5315In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID3695Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID1900022Intrinsic clearance in rat liver microsomes at 1 uM incubated for 45 mins in presence of NADPH by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1704736Antagonist activity at human 5HT2A receptor expressed in CHO-K1 cells assessed as inhibition of 5HT-induced calcium flux at 10 uM incubated for 60 mins at 37 degC followed by 15 mins incubation at room temperature and subsequent 5HT addition by calcium 4
AID16713Biodistribution in rat cerebellum at 3 hr after dose administration.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Resolution and in vitro and initial in vivo evaluation of isomers of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate: a high-affinity ligand for the muscarinic receptor.
AID566272Inhibition of human 5-HT2A receptor2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: de
AID1613980Inhibition of DGKalpha in OKT3-induced human Jurkat cells harboring SAP ShRNA assessed as restoration of restimulation-induced cell death at 1 uM measured after 24 hrs by trypan blue exclusion method2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
AID1637987Half life in mouse liver microsomes in presence of NADPH by LC-MS analysis
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID197157Value was obtained against serotonin-induced (5-HT2A) contractions in rat aorta rings1994Journal of medicinal chemistry, Aug-05, Volume: 37, Issue:16
Synthesis and atypical antipsychotic profile of some 2-(2-piperidinoethyl)benzocycloalkanones as analogues of butyrophenone.
AID1905972Metabolic stability in human liver microsomes assessed as intrinsic clearance at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Structure-Based Discovery and Optimization of Furo[3,2-
AID16705Biodistribution in rat blood at 3 hr after dose administration.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Resolution and in vitro and initial in vivo evaluation of isomers of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate: a high-affinity ligand for the muscarinic receptor.
AID1728078Metabolic stability in human liver microsomes assessed as half life in presence of NADPH by LC-MS analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
AID1152674Antagonist activity at human recombinant 5-HT2A receptor expressed in CHO-K1 cells assessed as inhibition of alpha-methyl serotonin-induced response treated 15 to 30 mins before agonist challenge by luminescence analysis2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
AID1905977Metabolic stability in rat hepatocytes assessed as hepatic extraction ratio at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Structure-Based Discovery and Optimization of Furo[3,2-
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID5377Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin1994Journal of medicinal chemistry, Dec-09, Volume: 37, Issue:25
1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist.
AID172548Inhibition of 5-HT induced pressor response in pithed rats, after intravenous administration of 0.02 mg/kg1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID1387457Displacement of [125I]DOI from human 5HT2A receptor expressed in HEK293 cell membranes2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID296885Displacement of [3H]ketanserin from 5HT2A receptor in Sprague-Dawley cortex membrane2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID1412489Antagonist activity at human 5-HT2A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced receptor activation preincubated for 15 mins followed by serotonin addition and measured after 1 hr by TGFalpha shedding assay2018MedChemComm, Mar-01, Volume: 9, Issue:3
Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT
AID63973Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarboxamides as selective 5-HT1A receptor agonists.
AID4135The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats)2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
N-[1-(2-Phenylethyl)pyrrolidin-3-yl]-1-adamantanecarboxamides as novel 5-HT2 receptor antagonists.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1613979Cytotoxicity against human Jurkat cells assessed as reduction in cell viability at 1 uM after 24 hrs by trypan blue exclusion assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
AID1728079Metabolic stability in mouse liver microsomes assessed as half life in presence of NADPH by LC-MS analysis2021European journal of medicinal chemistry, Jan-01, Volume: 209Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
AID4096Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID16907Biodistribution in rat striatum at 3 hr after dose administration.1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Resolution and in vitro and initial in vivo evaluation of isomers of iodine-125-labeled 1-azabicyclo[2.2.2]oct-3-yl alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate: a high-affinity ligand for the muscarinic receptor.
AID65881Inhibitory constant against binding of [125I]- IBZM to rat striatal membrane1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.
AID453248Inhibition of MDMA-induced behavioral suppression in rat assessed as earning of 20 food pellets at 0.1 mg/kg, ip administered 15 mins before MDMA challenge by food-reinforced operant task method2010Bioorganic & medicinal chemistry letters, Jan-15, Volume: 20, Issue:2
Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
AID6402Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1888640Half life in rat liver microsomes at 1 uM by LC-MS/MS analysis
AID6479Binding affinity towards human 5-hydroxytryptamine 5A receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID1905974Metabolic stability in rat hepatocytes assessed as hepatic clearance at 1 uM measured up to 60 mins in presence of NADPH by HPLC-MS/MS analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
Structure-Based Discovery and Optimization of Furo[3,2-
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID63537Binding affinity towards human dopamine receptor D42001Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
Current and novel approaches to the drug treatment of schizophrenia.
AID5311In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID180299Inhibitory concentration against 5-HT in conscious spontaneously hypersensitive rats (SHR)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Studies on quinazolines. 5. 2,3-dihydroimidazo[1,2-c]quinazoline derivatives: a novel class of potent and selective alpha 1-adrenoceptor antagonists and antihypertensive agents.
AID1900025Hepatic clearance in rat liver microsomes at 1 uM incubated for 45 mins in presence of NADPH by LC-MS/MS analysis2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer.
AID1739736Metabolic stability in ICR/CD-1 mouse liver microsomes assessed as compound remaining preincubated for 5 mins followed by NADPH addition and measured up to 45 mins by LC/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I.
AID1855073Binding affinity to rat frontal cortex homogenate membrane 5-HT2A receptor incubated for 10 mins2022Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
Positron Emission Tomography (PET) Imaging Tracers for Serotonin Receptors.
AID255315Percent inhibition against 5-hydroxytryptamine 2C receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID4036Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
AID752216Binding affinity to human 5-HT2A receptor by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID5238Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID1297685Inhibition of 5-HTP-induced head twitch response in ddY mouse at >=1 mg/kg, po administered 1 hr before 5-HTP injection measured after 30 mins relative to untreated control2016European journal of medicinal chemistry, Jun-30, Volume: 1165-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives.
AID1302520Inhibition of Set7/9 (unknown origin) expressed in Escherichia coli BL21 (DE3) by fluorogenic assay2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID5225Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand1992Journal of medicinal chemistry, Dec-25, Volume: 35, Issue:26
Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding.
AID36301Ability to displace [3H]-Prazosin binding to Alpha-1 adrenergic receptor2000Bioorganic & medicinal chemistry letters, Nov-06, Volume: 10, Issue:21
N-[1-(2-Phenylethyl)pyrrolidin-3-yl]-1-adamantanecarboxamides as novel 5-HT2 receptor antagonists.
AID4821Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Mixed 5-HT1A/D-2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1888639Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM measured after 45 mins by LC-MS/MS analysis
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID4128Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
N-[[1-(2-phenylethyl)pyrrolidin-2-yl]methyl]cyclohexanecarboxamides as selective 5-HT1A receptor agonists.
AID5314In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID1387455Inhibition of human VMAT2 expressed in HEK293 cell membranes assessed as reduction in [3H[-5HT uptake pre-incubated for 10 mins before [3H[-5HT addition and measured after 6 mins2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Discovery of Arylpiperidinylquinazolines: New Inhibitors of the Vesicular Monoamine Transporter.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID221608The inhibition of compound was measured for 8 min in head twitches of mice induced by 5-HTP(100 mg/kg, ip) at the dose of 0.3 mg/kg1992Journal of medicinal chemistry, Jan, Volume: 35, Issue:1
Syntheses and 5-HT2 antagonist activity of bicyclic 1,2,4-triazol-3(2H)-one and 1,3,5-triazine-2,4(3H)-dione derivatives.
AID752104Antagonist activity at serotonin-activated human recombinant 5HT-2A receptor expressed in HEK293 cells assessed as decrease in intracellular calcium level after 5 mins measured for 1 min by fluorescence assay2013European journal of medicinal chemistry, May, Volume: 63Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.
AID1302519Effect on ERalpha expression in human MCF7 cells at 10 to 100 uM after 48 hrs by immunoblotting analysis2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.
AID177735Inhibition of 5-HT induced pressor response in pithed rats, after intravenous administration1988Journal of medicinal chemistry, Dec, Volume: 31, Issue:12
Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID493017Wombat Data for BeliefDocking1993Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21
Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1798075Radioligand Labeled Binding Assay from Article 10.1021/jm070487n: \\Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.\\2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,941)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901006 (34.21)18.7374
1990's1098 (37.33)18.2507
2000's494 (16.80)29.6817
2010's293 (9.96)24.3611
2020's50 (1.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.68 (24.57)
Research Supply Index8.14 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index80.53 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials335 (10.83%)5.53%
Reviews117 (3.78%)6.00%
Case Studies36 (1.16%)4.05%
Observational0 (0.00%)0.25%
Other2,606 (84.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Ketanserin Effects on Peripheral Temperature and Lactate (KoPTaL) [NCT03646318]Phase 4120 participants (Anticipated)Interventional2018-09-01Not yet recruiting
Evaluation of the Effect of Ketanserine on Sublingual Microcirculation by SDF Imaging in Septic Patients on the Intensive Care [NCT01329887]Phase 310 participants (Actual)Interventional2011-03-31Completed
Effect of Ketanserin After LSD Administration on the Acute Response to LSD in Healthy Subjects [NCT04558294]Phase 124 participants (Actual)Interventional2020-10-16Completed
Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness [NCT04849013]Phase 116 participants (Actual)Interventional2021-08-11Completed
Efficacy of Pirfenidone Gel Combined With Modified Oxide Diallyl Disulfide (MODD) Versus Ketanserin for the Treatment of Diabetic Foot Ulcers [NCT02632877]Phase 1/Phase 260 participants (Actual)Interventional2014-01-31Completed
Role of the Serotoninergic System in Impulse Control Disorders in Parkinson's Disease [NCT03970239]45 participants (Anticipated)Interventional2019-05-13Recruiting
The Neurobiological Effect of 5-HT2AR Modulation [NCT03289949]Phase 1200 participants (Anticipated)Interventional2017-03-03Recruiting
Influence of Fenoldopam and Ketanserin on Function and Kidney Injury Parameters in Patients With Increased Risk of Acute Kidney Failure After Cardiac Surgery [NCT00557219]Phase 360 participants (Actual)Interventional2008-04-30Terminated(stopped due to Main cooperator finished cooperation)
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects [NCT05964647]Phase 120 participants (Anticipated)Interventional2023-12-01Not yet recruiting
The Role of 5-HT2A Receptor on Perception of the Self and Perception of Meaning in Healthy Volunteers [NCT02451072]25 participants (Actual)Interventional2015-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]